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Atherosclerosis is a chronic, complex arterial disease characterized by intimal 
lipid accumulation and inflammation. A unique lipid-binding molecule, namely 
cluster of differentiation 1d (CD1d), may impact atherosclerosis. Structurally, CD1d 
acts as a nonpolymorphic cell-surface receptor, resembling the major 
histocompatibility complex-I (MHC-I). While MHC-I restricts peptide antigen 
presentation to T cells, CD1d presents lipid antigens to T cells named 
CD1d-restrictedd T cells. Although increased expression of CD1d has been found in 
human plaques, the exact nature of CD1d-recognized lipids in atherosclerosis remains 
to be determined. Three groups of lipids may undergo oxidation in atherosclerosis 
producing atherogenic lipids: phospholipids, fatty acids, and cholesterol. The central 
hypothesis is that CD1d recognizes and present oxidative lipids to activate 
CD1d-restricted T cells, and trigger proinflammatory signal transduction  
In the first part of this study, oxidative phospholipids were identified and 
characterized as potential autoantigen for CD1d-restricted T cells. Derived from 
phospholipid 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine by 
oxidization, 1-palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine (PGPC) is 
 v 
commonly found in atherosclerotic plaques. Upon stimulation with PGPC, 
spleen-derived CD1d-restricted T cells produced higher levels of cytokines and 
proliferated at higher rates than those without PGPC stimulation. CD1d deficiency 
compromised the PGPC-triggered T cell activation, suggesting that PGPC may 
function as a potentially novel autoantigen for T cells in atherosclerosis. 
In the second part of this study, CD1d-mediated proinflammatory signaling 
was evaluated in murine models. Enhanced CD1 expression occurred in spleens of 
db/db mice with hyperlipidemia. Tumor necrosis factor-alpha (TNF-α) was increased 
in db/db spleen, while TNF-α receptor expression augmented in the db/db murine 
heart, in comparison with those in normal mice. The nuclear factor-κ B (NF-κB) 
expression was enhanced in the db/db heart, whereas CD1d-null mice showed lower 
NF-κB, implying the involvement of CD1d in inflammation of the spleen and heart 
tissues in the mice with hyperlipidemia.  
The current study has identified PGPC as a novel lipid antigen recognized by 
CD1d-restricted T cells in atherosclerosis. The animal study has also provided 
evidence that CD1d regulates NF-κB-mediated proinflammatory signaling. Hence, 
CD1d-restricted T cell responses to autolipid antigen and mediated inflammatory 
signal may represent a new molecular pathway that triggers cardiovascular tissue 
injury in atherosclerosis and hyperlipidemia.    
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                   Chapter 1: Background  
 
1. Inflammation in atherosclerosis  
Atherosclerosis is characterized by inflammation that occurred mainly in 
large- or medium-sized arteries. The initial phase is monocytes/macrophages 
activation, which is followed by effector T cells activation in response to antigens 
presented by antigen presenting cells (APCs). As the consequence of T cells activation, 
elevated levels of cytokines, as well as other pro-inflammatory mediators are detected 
(Figure 1). In innate way monocytes/macrophages are recruited to the injured site by 
some molecules, like P-selectin expressed endothelial cells. Macrophages can also 
take up lipid antigens and form foam cells. Therefore, high lipid level is a marked risk 
factor for developing atherosclerosis. Apolipoprotein E -/- (ApoE-/-) mouse model is 
deficient of ApoE, which is important for transport and metabolism of lipids. In 
ApoE-/- mouse model plasma cholesterol level is markedly elevated and an early and 
severe atherosclerotic lesions can be observed.  
Antigen presentation occurs in atherosclerotic lesions and trigger T cells 
responses. In atherosclerotic plaques, macrophages, dendritic cells and T cells can all 
be detected. Pevious studies have been focused on antigens that drive in this process. 
Low-density lipoproteins (LDL) can be modified into oxidized low density 
lipoprotein (OxLDL). OxLDL is an important self-antigen as phospholipids released 
from LDL can activate endothelial cells to express adhesion molecule (1). OxLDL 
–specific T cells have been detected in atherosclerotic plaque (2) and the transfer of  
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Figure 1.   Schematic representation of oxidized lipid-activated T lymphocyte 
immune responses in atherosclerosis. Monocytes adhere to endothelial cell 
expressing adhesion molecules when stimulated by OxLDL. Then monocytes migrate 
into the intima and differentiate into macrophages, which take up lipoproteins and 
form foam cells. Activated T cells secrete cytokines, which promote uptaking of lipids 
by macrophages, also cause smooth muscle cells in the media to migrate to the 
atherosclerotic lesion and proliferate.  
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this group of T cells exacerbates atherosclerosis (3). It has been also found that 
antibody titers to OxLDL and oxidized phospholipid (OxPL) are increased in 
atherosclerosis patients (4). It further proved the importance of oxPL in the 
development of atherosclerosis. Another antigen is heat shock protein (HSP) 65 that 
can activate auto-reactive T cells and aggravate fatty streak formation (5). 
Autoantibodies against beta2-glycoprotein I are also detected in atherosclerosis 
patients (6). 
As the responder to antigens presented by APCs, T cells regulate the 
magnitude of atherosclerosis. In atherosclerotic plaques cluster differentiation 4 
(CD4)+ cells are more abundant than cluster differentiation 8 (CD8)+ cells and these 
T cells are mainly found in shoulder area. CD4+ T cells are considered as 
proatherogenic and displayed activated/memory phenotype (7). ApoE-/- mice 
reconstituted with CD4+ T cells develop accelerated atherogenesis (8). Although less 
abundant than CD4+ cells, CD8+ cells also accelerate atherosclerosis development. 
Recent data also showed natural kill T (NKT) cells can recognize lipids presented by 
cluster differentiation 1(CD1) molecules and may contribute to the development of 
atherosclerosis. Cytokines secreted by activated T cells influence the progression of 
atherosclerosis. Interferon-γ (IFN-γ) is a major proatherogenic Th1 cytokines by 
activating monocytes/macrophages and dendritic cells (DCs). IFN-γ can also inhibit 
vascular smooth muscle cells (SMCs) and cause thinning and destabilization of 
fibrous cap of atherosclerotic plaque. Not only Th1 cells produce IFN-γ, CD8+ T cells 
and NKT cells are also sources of IFN-γ. Presently, the role of Th2 cytokines is poorly 
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understood. 
 
2. CD1 family 
2.1 Architecture and groups of CD1 proteins 
About a decade ago，it was recognized that lipid antigens can be presented by 
CD1 and can function as T cell antigens, which nourished the traditional concept of 
antigen presentation by major histocompatibility complex (MHC). Because of its 
recent discovery, CD1 remains unknown by immunologists and taken for granted to 
compare to MHC based on their similar structures.  
In contrast to MHC, which presents diverse peptides, CD1 is a family of 
nonpolymorphic cell-surface receptors that presents a growing number of identified 
lipids. However, they share a very similar structure consisting of heavy α chain and a 
non-covalently, stably linked β2-microglobulin (β2M) (Figure 2). The heavy chain is 
organized into three parts, α1, α2, α3, in which α1 and α2 mainly shapes the 
hydrophobic lipid binding pocket. It results in lipid buried and exposing other parts 
like antigen peptides as T cell binding and activating sites. Furthermore, α3 domain is 
associated with β2M and is highly conservative in CD1 family. Whole α chain is 
anchored in the cell membrane by transmembrane domain. Depending on the lipids 
presented by CD1 to T cells, the responder T cells can initiate adaptive immunity in 
microbe defense, or various immune reactions in tumor and autoimmune diseases.  
There are three classified groups in CD1 antigen-presenting molecules based 
on their structures and functions: CD1a-c represents group 1, CD1d represents group  
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Figure 2. Diagram of CD1d-lipid complex on APC. Lipid antigen binds to the 
hydrophobic binding pocket shaped by α1 and α2 and other exposed parts like 
peptides are T cell binding and activating parts. α3 domain is associated with β
2-microglobulin and is highly conservative. These three parts: α1, α2, α3 are 
organized into a heavy αchain. The whole αchain is anchored in the APC cell 
membrane by transmembrane domain.   
 
 
 
 
APC 
β2 α3 
α2 α1 
Lipid Antigen 
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2 (9), while CD1e constitutes the third group (10). CD1e has been found participating 
in lipid precession and loading instead of lipid presentation. To date, group 1 is found 
in all mammalian animals including human, rabbit (11-13).Whereas, only CD1d is 
expressed in mice and rat (Figure 3).  
2.2 Characteristics of CD1 binding groove and CD1 family ligands 
Due to a closer and elevated sitting of α1 and α2, the central binding groove of 
CD1 is deeper and narrower compared to MHC peptide binding groove (14). Two 
anti-parallel α-helices, α1 and α2 sit on the top of a six-stranded β–sheet platform, 
while different amino acids located in α1-α2 domain form specific CD1 isotype 
individual binding grooves. In the CD1 family, CD1a has the smallest binding groove, 
and CD1b has the largest and strikingly different one. No crystal structures of CD1c 
and CD1e have been described to date. However, more progress has been achieved in 
the CD1d field.  
As for CD1a, there are two groups of ligands identified. One is sulfatide  
demonstrated by the carbohydrate headgroup being the major epitope in activating T 
cell receptor (TCR) of CD1a-restricted T cells (15). The other group is 
didehydroxymycobactin lipopeptides (16). The ligands are considered to maneuver 
into CD1a binding grooves based on the little changes of CD1a structures in 
CD1a-ligand complex. With the largest binding groove in the CD1 family，CD1b is 
supposed to bind larger antigens. It has been proved that mycolate derived from 
mycobacteria and phosphatidylinositol and GM2 ganlioside (17) can be complexed 
with CD1b. Few ligands have been identified with CD1c and CD1e due to the lack of 
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Figure 3. Localization of CD1 genes in human and mouse chromosome. CD1a-e is 
fully expressed on human chromosome 1. In mouse, only CD1d is expressed and 
located on chromosome1. There are two isoforms of mCD1d: CD1d1 and CD1d2.  
SPNA1, spectrin alpha 1; spherocytosis. SPTA1, spectrin alpha erythrocytic 1  
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determinations of crystal structures.  
When it comes to CD1d, the classical ligand α-galactosylceramide (α-GC) has 
been proved to bind with both mouse and human CD1d (18). However, α-GC is 
derived from marine sponge and is not a natural ligand for CD1d. In a recent study 
phosphatidylcholine (PC) was identified as an endogenous ligand for CD1d (19). 
Following this finding, an increasing number of ligands have been identified: α-GC 
(20), sulfatide (21). In contrast to group 1 CD1 molecules, where extensive 
hydrophobic and van der Waals interactions are the main forces between ligands and 
CD1 molecules, the hydrogen bond network is the dominate force in CD1d. By 
studying the difference between human CD1d and mouse CD1d in ligand binding, it 
has been found that the structures and their binding with α-GC are very similar. The 
only difference is that tryptophan at position 153 in human isoform tilts galactose 
headgroup slightly which is replaced by glycine 155 and has no effect on binding 
capability.  
2.3 Tissue distribution of CD1 and expression in disease 
For a complete understanding of CD1 function, the expression of CD1d has 
been detected in both normal tissue and alteration in disease. Group 1 molecules are 
exclusively found on APCs and thymocytes. The peripheral expression of CD1a and 
CD1b is restricted to DCs, while CD1c is expressed on both DCs and B cells (22, 23). 
When it comes to disease, CD1a, CD1b and CD1c have been shown to be induced on 
DCs in dermal granuloma in Mycobacterium leprae (24). Melian et al has detected 
CD1a, CD1b, CD1c and CD1d expression in lipid-laden foam cells in atherosclerotic 
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lesions (25). Also CD1b and CD1c have been found to be increased in mycosis 
fungoides (26), and CD1-positive DCs have been presented in human breast cancer 
(27, 28). CD1c has been found to be decreased in B chronic lymphatic leukemia (29). 
In human peripheral blood, CD1d is mainly found in B cells, monocytes and 
activated T cells. Outside of the hematopoietic compartment, CD1d is found in 
hepatocytes, pancreas, kidney, breast, skin, testis, epididymis, small bowel, and colon 
(30, 31). For mouse hematopoietic cells, CD1d has been detected on B cells, T cells, 
macrophages and CD11c+DCs (32). The tissue distribution of CD1d in mouse is quite 
similar to human. In terms of disease, CD1d has been found to be overexpressed in 
inflammatory bowel disease, primary biliary cirrhosis, sarcoidosis and psoriatic 
lesions (30, 33). Moreover, human CD1d has been shown as upregulated in 
hepatocytes infected with hepatitis C virus (34). It is also noticed that CD1d is  
expressed in many tumors, like leukemia, brain tumor and myeloma (35, 36). 
According to these studies, CD1d expressed tumors can be lysed by α-GC expanded 
invariant natural killer T (iNKT) cells.  
 
3. CD1-restricted T cells  
3.1 Group 1 versus Group 2 CD1-restricted T cells 
T cells are the downstream cells that react with the antigens presented by 
CD1, so called CD1-restricted T cells. Accordingly, group 1 CD1 including CD1a, b, 
c activated T cells are classified as group1 CD1-restricted T cells. CD1d-restricted T 
cells are group 2 CD1-restricted T cells, which have apparently different expression 
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and function. CD1e is designated as group 3 CD1-restricted T cell and little is known 
about this group. The limited expression of group 1 CD1 in few cell types restricted 
the function of group 1 CD1-restricted T cells. Group 1 CD1-restricted T cells have 
been demonstrated to be linked to antigen-specific adaptive immunity. Meanwhile, 
they can provide immunity memory in a manner similar to MHC-restricted T cells. 
However, CD1d-restricted T cells are associated with innate immune system based on 
the activating antigens.  
3.2 Subgroups of CD1d-restricted T cells 
There are two distinct subgroups of CD1d-restricted T cells differentiated by  
TCR arrangement: type I, iNKT cells have highly conserved TCR repertoire 
consisting of Vα14-Jα281 (in mice) or Vα24-Jα18 (in human); type 2, noninvariant 
NKT cells have more diverse TCRs. Type I CD1d-resticted T cells are CD4-CD8- 
though a small subset expresses CD8. Previous studies have shown that Vα14  
exclusively uses Jα281 for junction (37). Later it was found that Vα14+-NK1.1+ cells 
were CD1d-specific (38). Ligand α-GC is specifically presented by CD1d and has 
been applied for CD1d-restricted T cells identification. Due to high conservation of 
CD1d and NKT cell receptor，human CD1d can present α-GC to mouse NKT cells 
and vice versa (39, 40). Type 2 noninvariant NKT cells are mainly detected in murine 
bone marrow and human liver and bone marrow (41). And little specific antigen has 
been identified except some group of self-derived glycolipid antigen, which is 
different from the one recognized by iNKT cells (40).  
3.3 Activation of CD1d-restricted T cells by microbial or self lipid antigens 
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It has been well established that CD1d-restricted T cells participate in the 
infection defense by recognizing microbial lipid antigens. CD1d-restricted T cells are 
activated by CD1d, antigen and TCR complex analogous to the way of 
MHC-restricted T cells activated by specific antigens. Foreign lipid antigens can 
either bind and presented directly by CD1d to activate CD1d-restricted T cells, or 
activate APCs to provide a co-stimulating signal to stimulate weakly autoreactive 
CD1d-restricted NKT cells (Figure 4). To date, very limited microbial antigens have 
been identified to activate CD1d-restricted T cells including mycobacterial lipids (42), 
monoglycosylceramides from sphingomonas species (43, 44), and lipophosphoglycan 
from Leishmania donovani  (45, 46).  
Another characteristic of both invariant and diverse CD1d-restricted T cells is 
self-reactive nature, which means responding to self-lipid antigens. Similar to binding 
and recognition of microbial lipid antigens, CD1d can present self-lipids to TCR and 
CD1d-lipid complex is the key stimuli for CD1d-restricted T cells (47). Some   
self-lipids identified for CD1d-resticted T cells activation require accessory 
co-stimulatory signals. For example, only with cytokines such as interleukin-2 (IL-2) 
supplemented, primary self-lipid-APCs complex can recognize NKT cells in vitro 
(Figure 4 ) (48). The activation CD1d-restricted T cells results in IFN-γ, interleukin-4 
(IL-4) and interleukin-10 (IL-10) production. IFN-γ can either induce CD1d 
expression on APCs and further enhances the activation of CD1d-restricted T cells, or 
modulates other inflammatory cells such as macrophages, DCs and Th1/Th2 balance. 
The production of IL-4 and IL-10 can lead to stronger Th2 response, which may  
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Figure 4. Activation of CD1d-restricted T cells by foreign or self lipid antigens.  
Foreign or self lipid antigens can either bind and presented directly by CD1d to 
activate CD1d-restricted T cells, or activate APCs and provide co-stimulating signal 
to stimulate weakly autoreactive CD1d-restricted NKT cells. The activation 
CD1d-restricted T cells results in Th1 cytokines like IFN-γ, and Th2 cytokines like 
IL-4 and IL-10 production.  
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explain some auto reactivity in autoimmune diseases. 
4. Oxidized Phospholipids  
4.1 Origin and structure of oxidized phospholipids 
OxPLs are self antigens mainly derived from cellular membrane phospholipids 
and phospholipids contained in circulating lipoprotein as low-density lipoproteins 
(LDLs) when undergoing oxidative modification. There is an increased level of 
OxPLs as decreased antioxidant defense or enhanced reactive oxygen species 
occurred in atherosclerosis (49) and cell apoptosis (50). One major phospholipid 
present in cell membrane and LDL is 
1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphrylcholine (PAPC). The 
chromatographic separation of PAPC oxidation products identified 
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphatidylcholine (POVPC), 
1-palmitoyl-2-glutaroyl-sn-glycero-3-phosphatidylcholine (PGPC), 
1-palmitoyl-2-(5,6-epoxyisoprostane E2)-sn-glycero-3-phosphatidylcholine (PEIPC) 
and oxidation products binding to CD36 called oxPCCD36. (Figure 5 ) (51).  
4.2 Receptors for OxPLs 
Based on structure diversity of OxPLs, it has been postulated that there are 
multiple receptors for OxPLs.  
Scavenger receptors. Cluster of differentiation 36 (CD36), a member of the 
scavenger receptor class B family has been indicated as a putative receptor for 
oxidized low-density lipoproteins (OxLDL). The acyl chains of OxPLs protruding 
from cell membrane are the key recognition sites for CD36 on macrophages (51). 
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Recent studies have shown that OxPLs derived from PAPC are ligands for CD36 (52). 
The interaction between platelet CD36 and OxPLs is associated with dyslipidemia 
and prothrombosis (53).  
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Figure 5. Chemical structures of oxidized phospholipids formed during oxidation 
of PAPC. PAPC oxidation products include 
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphatidylcholine (POVPC), 
1-palmitoyl-2-glutaroyl-sn-glycero-3-phosphatidylcholine (PGPC) 
1-palmitoyl-2-(5,6-epoxyisoprostane E2)-sn-glycero-3-phosphatidylcholine (PEIPC) 
and oxidation products binding to CD36 called oxPCCD36 . 
Oxidation 
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G-protein-coupled receptors (GPCRs). Parhami et al. has demonstrated that 
GPCR can be bound by OxPLs (54). Lipoprotein-associated phospholipase A2 
catalyzes the conversion of OxPLs into lysophospholipids, which are potent ligands 
for GPCR (55). Moreover, free oxidized fatty acids released from oxidized 
phosphocholine are ligands of GPCR (56). It was also shown that PEITPC can 
activate GPCRs prostaglandin E2 and prostaglandin D2 receptor (57). 
Toll-like-receptors (TLRs). TLRs consist of extracellular leucine-rich and 
intracellular Toll/IL-1 domains and are highly conservative during evolution. Twelve 
different TLRs have been identified, in which TLR1, 2 and 4 have been found 
expressed in both human and mouse atherosclerotic lesions, which are also induced 
by interleukin-1 (IL-l ) (58). Leitinger et al has found that OxPLs induced 
inflammation was TLRs related. (59).  Oxidized PAPC (OxPAPC) has been shown 
inducing interleukin-8 (IL-8) synthesis via TLR-4 and causing inflammatory effect 
(60).  
Peroxisome proliferator-activated receptors (PPARs). PPARγ and PPARα, 
nuclear receptor proteins regulating gene expression have been found to activate 
OxLDL. For instance, OxLDL can activate PPAPα dose-dependently on endothelial 
cells without affecting PPAPα protein expression level (61).  
4.3 OxPLs and atherosclerosis 
Various studies have proved that OxPLs play an important role in 
atherogenesis, including monocytes activation; extravasations and adhesion; 
inflammatory cytokines production and thrombogenesis induction (53, 62). Abundant 
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accumulation of OxPLs has been demonstrated from early fatty streaks to advanced 
atherosclerotic lesions. 
Monocytes activation. Previous studies have shown that OxPLs can activate 
monocytes binding to vascular endothelial cells by synthesizing adhesion proteins like 
connecting segment1 and monocyte chemotactic protein 1 (63) (Figure 6）. An 
alternative pathway suggested the involvement of lipoxgenase, which was 
demonstrated by a lipoxgenase inhibitor. The inhibitor decreased minimally modified 
low density lipoprotein (MM-LDL) and POVPC-induced binding of monocytes to 
endothelial cells (ECs) (64). 
Inflammatory cytokines production. Cytokines play important roles in the 
development of atherosclerosis. It has been found that the treatment of OxPLs 
induced the production of IL-8, interleukin-6 (IL-6), macrophage inflammatory 
protein-1 alpha (MIP-1α) and macrophage inflammatory protein-1 beta (MIP-1β) (65).  
IL-8 can be produced by macrophages and endothelial cells. and functions as 
chemoattractant for neutrophils, which causes migration and phagocytosis. IL-6 can 
be secreted by macrophages and T cells in response to specific microbial molecules, 
usually working as a proinflammatory cytokine and increase inflammatory cytokine 
production. MIP-1 including MIP-1α and MIP-1β is produced by macrophages 
stimulated with bacterial endotoxins, which act as chemoattractant to a variety of cells 
including monocytes, T cells, B cells and eosinophils. The complicate network 
between cytokines induced by OxPLs and immune cells initiates and promotes 
inflammatory process during atherosclerosis. 
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Thrombogenesis induction. The atherosclerotic plaque may rupture and 
cause thrombosis to form. OxPLs can enhance tissue factor expression in endothelial 
cells, which is the cell-surface receptor for factor VIIα, an important factor in 
thrombosis formation.  Furthermore, OxPLs can activate platelet and cause 
proatherogenic effect on the vascular wall. 
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             Chapter 2 Hypothesis and Specific Aims 
 
1.  Autoantigens and atherosclerosis:   
Currently, atherosclerosis is considered a chronic inflammatory disease 
involving both adaptive and innate immunity (66). Given abundant accumulation in 
the atherosclerotic plaque, lipids are suggested as the main target in this complex 
network. These lipids induce the infiltration of specific APCs and T cells in the 
atherosclerotic lesions, which boosts the inflammation and leads to the development 
of atherosclerosis.  
Initially, with a fat-rich diet, the large or medium sized arteries deposited the 
LDL in the wall, which is assembled from the fat-derived components like cholesterol, 
phospholipids. More and more LDL is accumulated in the artery wall and further 
modified into Ox-LDL under oxidative stress. Meanwhile, the mechanical changes, 
infection or immunological injuries prompt the release of chemokines from the 
vascular cells as the “bait”, which attracts peripheral monocytes to the injury site. 
Then these monocytes can extravagate the endothelial layer aided by endothelium 
adhesion molecules (67). The latter is up-regulated on endothelial cells in response to 
inflammation. After extravagation monocytes differentiate into macrophages or DCs, 
which can uptake lipids and come into being foam cells. Furthermore, these 
lipid-laden foam cells serve as the main APCs and recruit effective lymphocytes to the 
site, which amplifies the immunological response. In pathology from the earliest 
visible stage fatty streak to the advanced atheroma the lipid deposition, foam cells and 
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T cells can all be detected with different proportionally composition (68).  
As mentioned above there are three main lipid components involved in the 
atherosclerotic plaque: phospholipids, fatty acids and cholesterol. All of them are 
derived from oxidation of LDL which occurs predominantly in the intima of artery. 
Examination of foam cells isolated from both human and rabbit atherosclerotic aorta 
showed high levels of oxysterols. Among lipid components 7-keto-cholesterol is the 
major one followed with 7 beta-hydroxycholesterol and 7-alpha hydroxycholesterol 
(69). On the other hand, more and more evidence suggested the OxPLs play an 
important role in atherogenesis. Phospholipids are main components of cell 
membranes and susceptible to the oxidation stress presented in the atherosclerosis. 
OxPLs are more biologically active than unoxidized form. They can be recognized by 
CD36 scavenger receptor on macrophages or SMCs to promote foam cells formation 
(52). During atheroma progression OxPLs can regulate smooth muscle proliferation 
and ultimately lead to apotosis. The apoptotic cells attract more monocytes and 
lymphocytes: “inflammation bursts”. Meanwhile the retained OxPLs can activate 
platelet and cause thrombosis, which is a key step in the progress of atherosclerosis. 
When it comes to the fatty acid Waddington et al also demonstrated that fatty acid 
oxidation products are dispersed in the human plaques by using high-performance 
liquid chromatography (70). The precise mechanism of how fatty acid affects 
atherosclerosis development is currently unclear. 
The auto-lipid antigens recognized by CD1d in atherosclerosis are unclear. 
Several studies have indicated that three groups of oxidized lipids are involved in the 
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proatherogenic process: phospholipids, fatty acids, and cholesterol (71). Due to the 
harsh environment in artherosclerotic plaque, the oxidative lipids serve as the main 
antigens. Whether these molecules bind to CD1d leading to atherosclerosis is 
currently unknown.  Following the antigens identified, the downstream of antigen 
stimulated T cells responses is a very interesting field to explore. 
Above all, the process of lipid oxidation products interacting with other 
immunology molecules in the atherosclerosis is intriguing and remains to be further 
addressed. 
 
2. CD1 and atherosclerosis: 
CD1 is a family of cell surface receptors consisting of four distinct members, 
CD1a-d.  They are classified into two groups based on their structure and function: 
CD1a-c is group1 while CD1d is group 2 (9). CD1e gene was identified recently, but 
little is known about it (10). The genes of CD1 family are located at chromosome 1, 
1q22-23 together with MHC related gene and other inflammation associated genes. To 
date, group 1 is found in all mammalian animals including human, rabbit (11-13). In 
mice and rat, only CD1d is expressed. As for tissue distribution group, 1 CD1 is 
mainly found on APCs and thymocytes (72). CD1d is expressed more extensively 
including monocytes, DCs, B cells and activated T cells. Outside the hemopoietic part, 
CD1d is also detected in liver, kidney, spleen, breast, skin. This broad expression of 
CD1d implicates its pivotal role in the body defense.  
In contrast to MHC which presents peptide antigen, CD1 is a specific lipid 
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antigen present molecule. A growing number of lipid ligands from mycobacterial 
glycolipid to self phospholipids are revealed. In atherosclerosis, the CD1 family is 
found in lipid-laden foam cells while non-detected in normal arterial tissue (25). The 
lipids presented in atherosclerotic plaques contain oxidized cholesterol, fatty acid and 
phospholipids. The question is which lipids antigens are presented by CD1 and 
progressing into atherosclerosis.  
 
3. CD1-restricted T cells related inflammation in atherosclerosis 
T cells are the downstream cells that react with the antigen presented by CD1d, 
so called CD1-restricted T cells. To date, there are two characterized populations. One 
has invariant TCR alpha (Vα14/Jα18 in murine and Vα24/Jα18 in human) paired with 
TCR beta. Consistent with the marker of NKT cells: NKT lineage receptors 
specifically NK1.1, this population is a subset of NKT. Recently, another population 
of CD1 recognized T cells are revealed, which have diverse of TCR α and β (14). 
These T cells have shown Th1/Th2 cytokine secretion in response to diverse antigens. 
It is clear that NKT cells play important role in adaptive immunity. CD1 have been 
found in mycobacterial tuberculosis defense. The first CD1-restricted T cells were 
identified in culturing monocyte-derived DC with crude extract of M.tuberclosis. 
Double negative (CD4-CD8-) TCR αβ+ T cells were isolated and cytokine production 
observed (73, 74). The ligands identified in mycobacterial extract include mycolic 
acids, phosphatidylinositol mannosides and they are presented by CD1b, CD1c. Other 
studies also found sulfide and gangliosides can be presented by CD1a. For CD1d, one 
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sponge-derived α-Galcer is proved to be a specific ligand of CD1d. Accumulating 
evidence shows that CD1-restricted T cells, related to these CD1 molecules, can 
initiate immune response and modulate the development of the disease like 
autoimmune disease, tumor and allergy (75). Prosperous cytokines are induced in the 
CD1 stimulated T cell reactions. It is believed that Th1 cytokines like IFN-γ are 
proatherogenic while Th2 like IL-10 are antiatherogenic. The possible role of CD1 
gene family in atherosclerosis has been investigated in the mouse model (76, 77). In 
CD1d knockout mice, less aggravation of early atherosclerosis was observed and a 
large panel of cytokines was detected. Further investigation reported CD1 deficiency 
as protective, as noted by attenuation in the advancement of atherosclerosis (78). 
 
4. Inflammation in atherosclerosis with obesity and hyperlipidemia 
Coronary heart disease (CHD) due to atherosclerosis is becoming a leading 
cause of morbidity and mortality in type 2 diabetic patients (79). Type 2 diabetes is 
characterized by elevated LDL and triglyceride, lowered high density lipoprotein 
(HDL) (80, 81). Type 2 diabetes accounts for 95% diabetes mellitus and is caused by 
insulin resistance rather than insulin deficiency (82, 83). In diabetes high glucose 
level in the blood promotes the accumulation of plaques.  The high blood glucose 
level can also cause production of free radicals, which attack intact cells and cause 
cell damage. Therefore, diabetes accelerates atherosclerosis-related inflammation and 
diabetic patients are twice likely to have a heart attack.  
Nuclear factor-kappa B (NF-κB) is a family of transcription factors that 
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mediate inflammatory, immune responses and cell growth. It can be activated by 
various stimuli including proinflammatory cytokines, lipopolysaccharide, and reactive 
oxygen species. The process of activation of NF-κB included phosphorylation and 
subsequent proteolytic degradation of the inhibitory protein inhibitor of kappa B (IκB) 
by specific IκB kinases. Then the heterodimer of p50 and p65, free NF-κB could bind 
to κB sites located in nucthe leus (Figure 6). NF-κB pathway is activated in different 
stages of atherosclerotic plaques and contributed to initiation and progression of 
atherosclerosis. The activation of NF-κB has been detected in atherosclerotic plaques 
(84). In ECs NF-κB activity is elevated in arterial vessel exposed to disturbed blood 
flow and susceptible to atherosclerosis (85). In NF-κB signal pathway ECs 
inflammatory cells are recruited to the vessels by expressing Inter-Cellular Adhesion 
Molecule 1(ICAM-1), vascular cell adhesion molecule 1(VCAM-1), P- and 
E-selectins on ECs. 
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Figure 6. Activation of NF-κB by the TNF-α pathway. 
(1) Binding of TNF-α to its receptor recruits TRADD (TNF receptor-associated death 
domain protein), RIP (receptor-interacting protein) and TRAF2 (TNF 
receptor-associated factor 2). 
(2) TRAF2 activates IκB kinase (IKK). 
(3) The active IKK activates NF-κB by degrading the inhibitor protein IκB. 
(4) After NF-κB is activated, it may serve as a transcription factor or inhibit apoptosis.  
It has been found that the recognition of peptide bound with MHC to TCR of 
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T lymphocytes or the cross-linking of TCR by anti-TCR antibody orchestrate 
intracellular protein tyrosine phosphorylation events. This process further produces 
NF-κB. Whether the recognition of lipid bound to CD1d leads to NF-κB release and 
causes inflammation is still unknown. The stimulation of CD1d-restricted T cells by 
lipids can also cause release of tumor necrosis factor alpha (TNF-α). TNF-α can 
activate NF-κB by phosphorylation dependent ubiquitination and degradation of 
inhibitor of IκB proteins, which is carried out by a multiprotein kinase inhibitor of 
kappa B kinase (IKK) complex (Figure 6). Therefore, the release of TNF-α by 
stimulated CD1d-restricted T cells may have role to the direct effect of CD1d. 
    
Hypothesis: In summary CD1 plays an important role in hyperlipidemia 
related to obesity and atherosclerosis. The identification of antigens presented by CD1 
in atherosclerotic plaques remains to be elucidated. The central hypothesis is that 
oxidative lipids generated in hyperlipidemia associated with arthrosclerosis serve as 
autoantigens that activate NK-T cell and trigger proinflammatory signaling, leading to 
the enhancement of autoimmune or pro-inflammatory responses during the 
development of atherosclerosis lesion. CD1d-mediated pro-inflammatory signaling 
may occur in atherosclerosis-prone, obese animals and contributes to the 
cardiovascular dysfunctions triggered by hyperlipidemia.  
 
Specific Aims: 
Aim 1: To identify and characterize the lipid antigens recognized and 
  
27 
presented by CD1d to activate CD1d-restricted T cells in atherosclerosis. 
a). Conduct GC-MS analysis and biochemical characterization of 
atherosclerosis-prone lipids that function potentially as the ligands for CD1d. 
b). Determine whether the oxidized phospholipid PGPC acts as an autoantigen for 
CD1d stimulating CD1d-restricted T cells. 
Aim 2: To define whether CD1d mediates pro-inflammatory signaling and 
cardiovascular dysfunction in mice with atherosclerosis and obesity.   
a). Analyze whether CD1d deficiency alters cytokine production in 
atherosclerosis-prone or obese mice.  
b). Determine whether CD1d regulates pro-inflammatory signaling in mice with 
hyperlipidemia. 
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              Chapter 3 Methods and Materials 
 
1. Hypothetic prediction of lipid-CD1d interaction by computer stimulation 
The structures of the all candidates of lipid ligands were obtained from NIH 
Pubchem library. The 3D crystal structures of human and mouse CD1d were obtained 
from Protein Data Bank (PDB, Figure 7).  The binding capacities of the lipid 
molecules with the CD1d were analyzed by docking procedure SYBYL program, 
which was designed for determination of the interaction forces between the ligand and 
the target modeling. This part of experiment was assisted by Center for Experimental 
Therapeutics and Pharmacoinformatics, Department of Pharmacological and 
Pharmaceutical Sciences, College of Pharmacy, University of Houston. 
 
2. Gas-chromatography (GC) /mass-spectrometry (MS) of lipids 
       Mice were sacrificed by 100% carbon dioxide, skin was disinfected with 
70% ethanol. The thoracic cavity were open and heart was completely exposed. Blood 
was drawn from the heart, preferably from the ventricle by using a 26 gauge needle. 
The blood was drawn slowly to prevent heart collapsing. Approximately 1ml blood 
was collected into a tube containing 10 µl heparin sodium (APP Pharmaceuticals, 
LLC, Schaumburg, IL Cat # 27602). Then the same volume of PBS was added and 
centrifuged at a speed of 2000 rpm for 15 minutes. The supernatant was transferred to 
a new tube and immediately delivered for GC/MS analysis (Center for Experimental 
Therapeutics and Pharmacoinformatics, Department of Pharmacological and 
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Pharmaceutical Sciences, College of Pharmacy, University of Houston.) 
 
3. Cell lines and culture  
3.1 Culture of mouse CD1 transfected HEK293 (mCD1-HEK293 ) cells and HeLa 
cells 
      mCD1-HEK293 cell line was made by Corina Rosales (previous Ph.D 
graduate student) and stored in liquid nitrogen tank. HeLa cells were purchased from 
American Type Culture Collection (ATCC) (Manassa, VA, Cat # CCL-2). For the use 
of culture, cells were quickly thawed in 37°C and grown in complete culture medium- 
Dulbecco’s Modified Eagle’s Medium (DMEM, Sigma-aldrich, St Louis, MO, 
Cat#D5796) supplemented with 20% fetal bovine serum (FBS, Atlanta biologicals, 
Lawrenceville, Ga, Cat#S11050), 1:100 (v/v) diluted antibotic antimyotic solution 
(Sigma-aldrich, St Louis, MO, Cat#A5955). For sub-culture, cells seeded in 75cm2 
flasks were treated with EDTA/Trypsi (Sigma-aldrich, St Louis, MO, Cat# T4049) for 
5 minutes at 37°C  
 
 
 
 
 
 
 
  
30 
 
 
 
 
 
 
 
 
Figure 7. Chemical structures of lipids commonly found in atherosclerotic lesions. 
There are three main lipid components involved in the atherosclerotic plaque: 
phospholipids, fatty acids and cholesterol. Oxidation products of these lipids 
predominantly exist in atherotic plaque. 
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incubator. Then 104 suspended cells were seeded into 10 ml pre-warmed complete 
culture medium. Only cells less than ten passages were used in the following 
experiments. For preservation, cells were suspended in 90% FBS mixed with 10% 
sterile DMSO then kept into 2 ml cryo-vial (Phenix research products, Candler, NC, 
Cat # C40F ) and stored in liquid nitrogen following a slowly frozen procedure 
(around 1 °C decrease per minute).  
3.2 Culture of MOLT-4 cells 
MOLT-4 cell line was purchased from ATCC (Cat # CRL-1582). Cells were 
quickly thawed in 37°C and grown in complete culture medium-RPMI 1640 
(Invitrogen, Carlsbad, CA, Cat#72400) supplemented with 20% FBS, 1:100 (v/v) 
diluted antibotic antimyotic solution. The subculture and freezing methods were the 
same as described above.                                                                                             
3.3 Culture of DN32.D3 
DN32.D3 is a murine NKT hybridoma cell line including Vα14-Jα18 TCR, 
which was kindly provided by Dr. Steven Porcelli (Albert Einstein College of 
Medicine, New York, NY). Cells were cultured in complete medium consist of RPMI 
1640, 20% FBS, 1:100 (v/v) diluted Antibotic antimyotic solution, 50µM 
2-mercaptoethanol (Sigma-aldrich, St Louis, MO, Cat #6250)  and 1mM HEPES 
(4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) (Sigma-aldrich, St Louis, MO, 
Cat #0891). The subculture and frozen methods are the same as described above.  
  3.4 Culture of Peripheral Blood Mononuclear Cells (PBMCs) 
PBMCs are mixed cells consisting of lymphocytes, monocytes and 
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macrophages. The lymphocytes include T cells (CD4 and CD8 ~75%), B cells and 
NKT cells (~25% combined). The isolation of PBMCs was processed by Ficoll 
according to density gradient method. Briefly, 5ml buffy coat peripheral blood was 
diluted with two volumes of PBS. Then 3 ml of Ficoll was layered up on the top. 
With 800 g centrifuge for 30 minutes at RT, human PBMCs can be visible at 
PBS/Ficoll interface. PBMCs were carefully harvested and washed with PBS twice. 
Isolated cells were dispensed in 6-well plates and cultured in RPMI 1640 
supplemented with 20% FBS, 1:100 (v/v) diluted antibotic antimyotic solution 
stabilized. The frozen method is the same as described as above.  
3.5 Isolation and culture of mouse spleen cells 
Spleen cells are consisted of lymphocytes, granulocytes and other immune 
cells. The procedure to isolate spleen cells is described as below:  
Mice were sacrificed by 100% carbon dioxide. Skin was disinfected with 
70% ethanol, the abdominal cavity open and spleen removed. Spleen was placed 
into cold PBS and mashed by using the plunger of the syringe and passed through 
70 µM cell strainer (BD science, Franklin Lakes, NJ, Cat # 352350).  Red cell lysis 
buffer (Biolegend, San Diego, CA, Cat # 420301) was applied to remove red blood cells. 
After washing with PBS by centrifuging at 400g twice, cells were cultured in RPMI 
1640 supplemented with 20% FBS, 1:100 (v/v) diluted antibotic antimyotic solution 
stabilized. The frozen method is the same as described as above.  
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4. cDNA cloning and transfection  
4.1 Generation of hCD1d cDNA: 
MOLT-4 is derived from human lymphoblast and has rich CD1d expression. 
RNA isolation from MOLT-4 was processed by using RNeasy Mini Kit (Qiagen, 
Valencia, CA, Cat #74104). First 107 cells were centrifuged at 300g for 5 minutes 
and cell pellet was loosened by buffer RLT. Then cell lysate was pipetted into 
QIAshredder column and centrifuged for 2 minutes. 70% ethanol was added into 
homogenized lysate for precipitation and buffer RW1 was used for wash. Buffer 
RPE was used for final RNA elution. Isolated RNA was stored in -80°C for future 
use. Complimentary DNA (cDNA) was synthesized by using superscript III 
Platinum Two-step quantitative real time polymerase chain reaction amplification 
(qRT-PCR) Kit (Invitrogen, Carlsbad, CA, Cat #11734-050) under the instructions 
of the manual. The RNA reaction system was consisted of 2 x RT reaction mix 10µl; 
RT enzyme mixes 2µl; RNA 8µl. All components were mixed and incubated at 25°C 
for 10 minutes then 42°C for 50 minutes. The reaction was terminated at 85°C for 5 
minutes, and then chilled on ice. And 2U of E.coli RNase H was added and 
incubated at 37°C for 20 minutes. The synthesized cDNA was stored in -20°C until 
use. Then cDNA was used for PCR by using Platinum Pfx DNA polymerase 
(Invitrogen, Cat # 11708-013). The RT-PCR reaction system consisted of Plantinum 
Pfx buffer 5µl, 10mM dNTP 1.5µl, 50mM MgSO4 1µl, primers 1.5µl each, template 
DNA 100ng, 10%DMSO 2.5µl,  Pfx DNA polymerase 0.4µl, and distilled 
water(ddH2O) to 50µl.  The primers were used for amplifying hCD1d: Forward, 
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5'-3' GCGATATGGGGTGCCTGCTG, Reverse, 5'-3' 
AACAGGACGCCCTGATAGGAAGTTTGC. The PCR amplification was as 
following: denaturing at 94°C for 15 seconds, annealing at 55°C for 30 seconds, 
extending at 68°C for 1 minute. Total 30 cycles were performed.  
4.2 cDNA subcloning and plasmid construction: 
      The cloned gene hCD1d was ligated into Zero Blunt PCR cloning plasmid 
(Invitrogen, Cat # K270020)). The ligation reaction system included 5µl T4 DNA 
ligase buffer, 2µl DNA, 1µl vector, 1µl T4 DNA ligase (Invitrogen, Cat # 15224-041) 
and 1µl ddH2O. The reaction was incubated in room temperature for 5 minutes. The 
ligated product was separated with unligated reaction components by running on 0.8% 
agrose gel (Invitrogen, Cat # 15510-027). Predicted size band was excised under the 
observation of UV-light. The cut gel band was isolated by using QIAquick Gel 
Extraction Kit (Invitrogen, Cat # 28704). First, three volumes buffer QG was added to 
1 volume gel and incubated at 50°C for 10 minutes until the gel is dissolved. Then 
one volume of isopropanol was added and sample was transferred to a QIAquick 
column for spinning. Buffer PE was used for washing the sample collected in the spin 
tube then buffer EB was used for eluting DNA. Isolated DNA was further digested 
with restriction endoneuclease enzymes XhoI (New England Biolabs NEB, Ipswich, 
MA, Cat # R0146S), KpnI (New England Biolabs NEB, Ipswich, MA, Cat # R0142S). 
The endonuclease digestion reaction system is as following: 3µl DNA, 1µl enzyme, 
0.2µl BSA, 2µl enzyme buffer. The reaction was incubated at 37°C for one hour. 
Digested products were separated by running on 0.8% agrose and excised for isolation 
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by QIAquick Gel Extraction Kit as described above. Using sticky ends produced by 
digestion hCD1d was cloned into pEGFP-N3 plasmid with CMV promoter (Clontech, 
Mountain View, CA, Cat # 6080-1) (Figure 8). The cloned plasmid was first verified 
by restriction endonuclease digestion (Figure 9a). All plasmids were finally verified 
by sequencing (Seqwright, Houston, TX) (Figure 9b). The sequencing primers applied 
are: GFPN3primer, 5'-3'GCTAGCGCTACCGGACTCAGATCTCGA, GFPprimer, 
5'-3'GTACCAGGACGACCCTAAGCA.  
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Figure 8. Construction of CD1d-pEGFP-N3 plasmid.  The cloned gene hCD1d 
was ligated into Zero Blunt PCR cloning plasmid. The ligated plasmid was further 
digested with restriction endonuclease enzymes XhoI and KpnI. Using sticky ends 
produced by digestion hCD1d was cloned into pEGFP-N3 plasmid with CMV 
promoter. 
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Figure 9.  Verification of CD1d cDNA sequence in hCD1d-pEGFP- N3 plasmid. 
a. hCD1d-pEGFP-N3 was cut by KpnI, XhoI. There are 4.7kb and 1.1kb bands 
observed after endonuclease digestion and separated on 0.8% agrose. Lanes 1, 2 stand 
for different colonies. b. Demonstration of sequencing results of hCD1d-pEGFP-N3 
by GFPN3primer, 5'-3'GCTAGCGCTACCGGACTCAGATCTCGA. “ATG” indicated 
in the picture represents the start code.  
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4.3 Plasmid transfection and stable cell line set up: 
To ensure high efficiency of transfection, Attractene Transfection Reagent 
(Qiagen, Cat # 301105) was used and HEK293 (ATCC, Cat # CRL1573) was selected 
as host cells. The transfection was carried out according to the manufacturer’s 
instructions. Briefly, 4x105 HEK293 cells were seeded in 6-well plate in complete 
culture medium the day before transfection. For transfection, 1.2 µg DNA was diluted 
in 100µl culture medium without serum. Then 4.5 µl Attractene Transfection reagents 
(Qiagen, Cat # 301005) were added and mixed by vortex. After 15 minutes incubation, 
the mixture was added into cells by drop-wise. After 24 hours, the efficiency of the 
transfection was observed under florescence microscope and the expression of 
transfected CD1d was detected by Western-blotting assay. Plasmids 
hCD1d-pEGFP-N3 and pEGFP-N3 only were transfected then selected by HyClone 
G418 (600µg/ml) (Thermoscientific, Barrington, IL Cat # SV30069.01) after 48 hours. 
Survived colonies were picked up and cultured as stable cell lines. 
 
5. Analysis of cell proliferation 
5.1 Thymidine incorporation into DNA 
In order to detect mCD1-restricted T cells responses to lipids, pulsed APCs 
with lipids were co-cultured with responder T cells and thymidine uptake by T cells 
was observed. 4 x 105 mouse DCs or 5 x 104 mCD1d stable cells were incubated with 
0-15µg/ml lipids in 48-well plate overnight at 37°C. Then, all cells were irradiated in 
3000 rad and extensively washed before added into 4 x 104 mouse spleen cells or 5 x 
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104 DN32.D3. Sixteen hours later, 1µM 3H thymidine (GE healthcare Amersham 
biosciences, Pittsburgh, PA, Cat # TRK296) was added into each well. After 24 hours 
incubation, DNA was extracted from cells by using ice cold 5% trichloroacetic acid 
(TCA, EMD chemicals, Raleigh, NC, Cat # TX1045-1). After treated with TCA for 30 
minutes at 4°C, precipitated DNA was collected and washed by PBS once, then 
dissolved in 0.5N NaOH (Sodium hydroxide, Sigma-aldrich, Cat # S8045) /0.5% 
SDS(Sodium dodecyl sulfate, USB, Cleveland, Ohio, Cat # 21651). The DNA was put 
in scintillation vial for beta counter (Beckman Coulter, BioSurplus Inc, San Diego, 
CA, model # LS6500) reading. All assays were done in triplicate. 
5.2 Proliferation assay of splenocytes 
Since mouse spleen cells contain both APCs (macrophages and monocytes) 
and reactive T cells, treatment of mouse spleen cells with lipids can be used directly 
for observing ligand actived CD1d-restricted T cells response. In this experiment, 
BALB/c and CD-/-BALB/c spleen cells were treated with lipids and thymidine uptake 
was observed. Briefly, 4 x 105 mouse spleen cells were incubated with 0-15µg/ml 
lipids in 48-well plates overnight at 37°C. Sixteen hours later the proliferation of 
mouse spleen cells was measured by reading 3H thymidine uptaken as described 
above.  
Spleen cells from both BALB/c and CD1-/-BALB/c were used for 
measurement of CD1d-restricted T cells response to PGPC and PAPC. Fresh splenic 
cells 4x105 from BALB/c or CD1-/-BALB/c were seeded in 96-well plates and treated 
with increasing concentrations of PGPC and PAPC (0.3-9.6 µg/ml). After 72 hours, 
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cells proliferation was measured by Quick Cell Proliferation Assay kit II (Biovision, 
Moutain View, CA, Cat # K302-500). Briefly, 10µl WST reagent was added to each 
well and cells were incubated at 37°C for 3 hours. The absorbance of the treated 
samples at 415 nm was measured and 655 nm was used as reference wavelength.  
 
6. Lipids binding assays 
6.1 Lipid preparation and storage 
PGPC (Avanti polar lipids Alabaster, Alabama, Cat # 870602), PAPC (Avanti 
polar lipids, Cat # 850459) were dissolved in 100% ethanol at a stocking 
concentration of 10mg/ml and stored at 4°C. Cholesterol (Sigma-aldrich, Cat # C3045) 
was dissolved in chloroform at a stocking concentration of 10 mg/ml and stored at 
4°C. 3H-7-K-Cholesterol(3H-7-K-Cho) dissolved in ethanol (American Radiolabeled 
Chemicals Inc, St. Louis, MO, Cat # ART1174) was stored at 4°C and diluted in PBS for 
experimental use. 
6.2 Lipid binding assay 
For assessment of binding capacity of lipids to CD1d, mCD-HEK293 cells are 
applied for lipid binding assay. Stable cell line mCD1-HEK293 and HEK293 were 
seeded into 96-well plate (104/well) for overnight (O/N). The next day, complete 
culture medium in cells was removed and serum-free medium was replaced. Then 
cells were shaken on ice for 15 minutes. A series of dilution of labeled 3H-7-K-Cho 
(0.005, 0.01, 0.5, 2, 3.5, 5 M) was added into cells and incubated for another 15 
minutes on ice. Then cells were washed with PBS twice and lysed by scintillation 
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liquid. The radioactivity was read by a beta-counter. For inhibitor competitive assay, 
PGPC and cholesterol were tested. After seeded in 96-well plate (104/well) for O/N, 
cells were washed by PBS twice, replaced with serum-free medium and incubated 
with 4 nmols of lipids for 15 minutes on ice. After washing with PBS twice, cells 
were incubated with 3H-7-K-Cho (0.005, 0.01, 0.5, 2, 3.5, 5 M) on ice for another 15 
minutes. The isotope reading method is described as above. Blank control was set up 
with the same dose of 3H-7-K-Cho without cells.  
 
7. Fluorescent detection of lipid loaded cells 
Mouse spleen cells were seeded 2x106 per well in 1ml full medium in chamber 
slides. These cells were treated with PGPC 4.8 µg/ml overnight and used for lipid 
analysis by Nile Red (Sigma, Cat # N3013)staining according to standard protocol 
(87). In brief, PGPC treated cells were washed in PBC with 2 mg/ml albumin twice, 
then 1.5% glutaraldehyde was applied for 5 minutes to fix cells. Stocking solution of 
Nile Red was diluted to 100 ng/ml to stain cells for 5 minutes. 
4′,6-Diamidino-2-phenylindole dihydrochloride (Dapi, Sigma Cat # D9564) was 
diluted to 3µM for cell nuclei staining at 37°C for 10 minutes. HeLa cells 2x105 per 
well were plated in 1ml full medium in chamber slides. The hCD1d-GFPN3 and 
GFPN3 plasmids were transfected into HeLa cells by attractene transfection kit. 
Tansfection efficiency was determined by observing GFP fluorescence.  
Approximately 80% of the cells were successfully transfected with plasmids. The 
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transfected cells were treated with PGPC 4.8 µg/ml for 3 hours then used for Nile Red 
staining as described above.  
 
8. Measurement of cytokine production 
In addition to thymidine uptake assay, direct cytokine production is also a 
strong indication for lipid activation of responder T cells. To assay the cytokine 
production, a total of 15µg/ml lipids were incubated with APCs (mCD1-HEK293 and 
hCD1d-HEK 293) 4-5 hours at 37°C. Then stimulator APCs were fixed with 0.05% 
glutaraldehyde（Sigma Aldrich Cat # G7651）in PBS for 30 seconds and the same 
volume of 0.4 M glycine (Sigma Aldrich, Cat # 410225) was added to stop the 
reaction. Fixed cells were washed in DMEM twice and APCs culture medium once 
before added into the responder T cells. Cytokines were collected from supernatant 
and analyzed at time points of 6 hours, 24 hours, and 48 hours. BD Cytometric Bead 
Array (CBA) mouse Th1/Th2 cytokine kit (BD Bioscience, Franklin Lakes, NJ, Cat # 
551287) was applied for measuring IL-2, 4, 5, IFN-γ and TNF-α. The principle for 
this method is as following: The capture bead has been conjugated with specific 
antibodies, for example, anti-IL-2; the detection reagent is a mixture of phycoerythrin 
(PE)-conjugated antibodies. When the sandwich complexes capture bead, analyte and 
detection reagent is formed, the fluorescence is analyzed in proportion to the amount 
of bound analyte. Flow cytometry was used for measuring the fluorescence and 
sample was quantified by using standard curve. All assays were done in triplicate.   
  
43 
9. Induction and detection of CD1d expression in PBMCs 
Freshly isolated PBMCs 108 were seeded in 6-well plates then pulsed with 15 
µg lipids for 24 hours. After removing culture medium, cells were washed by PBS 
twice and lysis buffer were added. The cells were lysed for 10 minutes at room 
temperature. Cell lysates were transferred into eppendorf tube and centrifuged at 
13,000x g for 15 minutes at room temperature. The supernatant was collected and 
stored in -80°C freezer for future use. 
Protein concentration was determined with BCA reagent protein assay kit 
(Pierce, Rockford, IL, Cat # 23227). The basic procedure is as following: Firstly mix 
reagent A and B at the ration of 50:1. Next 2.0 ml mixture was introduce into 0.1ml 
sample (standard and unknown) and mix. The mixture was incubated at 37°C for 30 
minutes then read at 562 nm by spectrometer (Biorad, Ultramark). 
The CD1d expression was detected by Western-blot analysis. Total 20µg 
protein samples mixed with 6 x loading buffer (NEB, Cat # B7021) was first boiled at 
95°C for 3 minutes, then separated on 4–15% gradient polyacrylamide gel (Biorad, 
Hercules, CA, Cat # 1611158) and transferred onto PVDF membrane. After transfer, 
the membrane was blocked with 3% nonfat milk (Santa Cruz Biotechnology Inc, Santa 
Cruz, CA, Cat # SC2324) for one hour at room temperature. PVDF membrane was 
then probed with anti human CD1d antibody (Santa Cruz Biotechnology Inc, Cat # 
SC19632). GAPDH (Abcam, Cambridge, MA, Cat # ab9483) was used as internal 
standard for control.  
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10. Flow cytometry 
10.1 Intracellular IFN-γ immunostaining 
To further identify IFN-γ secreting cells, we treated BALB/c mouse spleen 
cells with 4.8µg/ml PGPC for 24h and stained these cells with anti-IFN-γ-Alexa647 
(BD Bioscience, Cat # 557735) and anti-mouse cluster differentation3 (CD3) - 
Fluorescein isothiocyanate (FITC ) (BioLegend, San Diego, CA, Cat # 100204) 
antibodies. The cell preparation for flow cytometry is as following: 106 cells were 
collected by centrifugation at 1000 rpm for 5 minutes, and resuspended cells in 0.5 ml 
PBS. Thereafter, cells were fixed by 2% paraformaldehyde (USB Corporation, 
Cleveland, OH, Cat # 19943) at 37°C for 10 minutes. Tube was chilled on ice for 1 
minute. Cells were permeabilized by ice-cold 100% methanol for 30 minutes on ice. 
After centrifugation incubation buffer (0.5 g BSA in 100 ml 1xPBS) was add to 
suspend cells. Then cells were incubated with anti-IFN-γ-Alexa647 0.5 µg for 40 
minutes at room temperature. Cells were rinsed with incubation buffer twice. Cells 
were incubated with anti-mouse CD3-FITC 0.5 µg for 40 minutes at room 
temperature. Cells were rinsed with incubation buffer twice. Cells were resuspended 
in 200 µl incubation buffer. The cells were kept in ice and light-avoided before flow 
cytometry analysis. Data was acquired by BD-LSRII flow cytometer. 
10.2 Flow cytometric staining 
Mouse spleen cells were washed using buffer (0.1% sodium azide, 0.1% BSA 
in PBS) twice and 106 cells were suspended in 100µl of wash buffer and used for 
1.0µg tetramerized mCD1 staining together with anti-mouse CD3-FITC.  PBS-57 
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loaded CD1d tetramer (NIH tetramer core facility, Atlanta, GA) was used as positive 
control and unloaded CD1d tetramer (NIH tetramer core facility, Atlanta, GA) as 
negative control. The tetramer mCD1 was prepared from biotinylated mCD1 
monomer (NIH tetramer core facility, Atlanta, GA). The principle of the approach is 
summarized in the Figure 10.                                                                                                                                
The tetramer staining method is as follows: CD1d tetramer was spinned at 
13,000 g for 3 minutes in a chilled microcentrifuge. And 106 mouse splenic cells was 
washed with wash buffer (0.1% sodium azide, 0.1%BSA in PBS) and resuspended in 
200 µl residue liquid. 0.5 µg CD1d tetramer was incubated with cells for 60 minutes. 
Cells were washed with 2 ml wash buffer and resuspended in residual liquid 200 µl. 
Anti-mouse CD3 antibody was incubated with cells at room temperature for 60 
minutes. Cells were washed twice with wash buffer and resuspended in residual liquid 
200µl. The flow cytometric data were acquired using BD-LSRII. Samples from 
ApoE-/-C57BL/6J (The Jackson Lab , Bar Harbor, Maine, Stock # 002052. 12 months 
old, male only) and WT C57BL/6J (The Jackson Lab, Stock # 000662. 12 months old, 
male only) were examined.  
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Figure 10.  CD1d tetramer preparation. Step 1: The biotin binding sites on the 
added streptavidin are bound with biotinylated CD1d monomer to form tetramer. 
Excess biotinylated monomer is present.  Step 2: More biotinylated CD1d monomers 
were bound to streptavidin, still monomer is in excess. Step 3: Almost equimolar of 
CD1d biotinylated monomer and strepavidin is present. Step 4: Strepavidin is in 
excess. 
 
 
Step 1: Monomer 
Excess 
Step 2: Still Monomer 
Excess 
Step 4: Streptavidin 
Excess 
Step 3: Nearly Equimolar 
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10.3 CD1d expression detection by flow cytometry 
Spleen cells from db/db C57BL/6J (The Jackson lab, Stock # 000642) and WT 
C57BL/6J were isolated as descried above. Freshly isolated spleen cells 106 were 
suspended in 100µl of wash buffer and used for PE-anti-mCD1d (BD Science, Cat # 
553846) staining. Before staining with PE-anti-mCD1d, anti-mouse CD16/32 mAb 
(BD Science, Cat # 553141) was applied for saturating unspecific binding. FACS data 
were acquired using BD-LSRII. Samples from db/dbC57BL6 (two 2months old and 
two12 months old mice, male only) and WT C57BL/6J (two 2months old and two 12 
months old mice, male only) were examined.  
 
11. Reverse-transcription polymerase chain reaction (RT-PCR) for detection of 
T-cell receptor (TCR) mRNA 
11.1 T-cell repertoire analysis 
RNA was isolated from sorted cells with PGPC loaded CD1d tetramer and 
CD3 staining double positive by using RNeasy mini kit as described above. 
First-strand cDNA synthesis was performed using superscript III Platinum Two-step 
qRT-PCR Kit as described above. 
11.2 RT-PCR for detection of TCR mRNA 
PCR amplification was performed as described elsewhere (86). In brief, the 
murine TCR repertoire was analyzed using a panel of primers specific for TCR Vα14 
(5’-AGACCCAAGTGGAGCAGAGTCC-3 ， 3’- 
ACCAGGTATGACAATCAGCTGAGTCC-5’ ）  and Vα14 paired with 
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Jα281(5’-GGGAGATACTCAGCAACTCTGG-3’ ， 
3’-TCCCAGCTCCAAAATGCAGC-5’) for mouse TCR repertoire analysis. Also the 
single reaction GAPDH specific primer pair 
(5’-TGATGACATCAAGAAGGTGGTGAAG-3’, 3’- 
TCCTTGGAGGCCATGTGGGCCAT-5’) was used as an internal PCR control for 
verification of cDNA integrity and the fidelity of the single PCR reactions. The first 
PCR cycle started with 4 minutes in a hot block at 95°C and then at 95°C (15 
seconds), 58°C (30 seconds) and 72°C (90 seconds) for 35 cycles. PCR products were 
analyzed on a high-resolving polyacrylamide gel electrophoresis system. 
  
12. Murine models for atherosclerosis and obesity 
BALB/c, CD1-/-BALB/c, C57BL/6J, ApoE-/-C57BL/6J， db/dbC57BL/6J  
were housed and bred under specific pathogen-free conditions in the Animal Care 
Facility at The University of Texas Health Science Center and all mice study 
protocols were approved by the Animal Welfare Committee of The University of 
Texas Health Science Center. 
12.1 ApoE -/- Mice 
ApoE is 299 amino acids long lipoprotein mainly synthesized in the liver, also 
found in spleen, brain and kidneys. Lipoprotein is the molecule formed when protein 
binds lipid. ApoE is a major lipoprotein consisting very low-density lipoproteins 
(VLDLs). VLDLs remove extra cholesterol from blood stream by transporting 
cholesterol to the liver. There are three slightly different alleles of ApoE called e2, e3 
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and e4 in which e3 is the most common form. ApoE-/- mouse model has 
hyperlipidemia and develop atherosclerosis in the early age when fed western-type 
diet due to lipoprotein metabolism dysfunction. The atherosclerotic plaque lesion 
components are similar between ApoE-/- and human. This mouse model has been 
used for several years to study the impact of risk factors causing atherosclerosis, and 
pathological mechanism during atherosclerosis. Wild type (WT) mouse strain 
C57BL/6JJ has a very low genetic variation between siblings. Therefore, ApoE-/- was 
built on this wild type mouse model.  
12.2 db/db mice  
Leptin can regulate fullness and energy use by binding to leptin receptor 
expressed in the hypothalamus. Db/db mouse has a mutation on leptin receptor 
causing loss of function. There is significant obesity, fasting hyperglycemia, and 
hyperinsulinemia in db/db mouse model. It provides an ideal diabetic atherosclerosis 
mouse model for studying the mechanism of diabetes-accelerated atherosclerosis and 
exploring the therapeutic approaches.  
12.3 Blood lipid and glucose analysis 
Mice were sacrificed by 100% carbon dioxide, skin was disinfected with 70% 
ethanol. The thoracic cavity was open and heart was completely exposed. Blood was 
drawn from the heart, preferably from the ventricle by using a 26 gauge needle. The 
blood was drawn slowly to prevent heart collapsing. Approximately 1ml blood was 
collected into a tube containing 10 µl heparin sodium (APP Pharmaceuticals, LLC, 
Schaumburg, IL Cat # 27602). Then the same volume of PBS was added and 
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centrifuged at a speed of 2000 rpm for 15 minutes. The supernatant was transferred to 
a new tube and immediately delivered for lipid and glucose level analysis (Equiche 
Laboratories Inc, Houston, TX). 
12.4 Tissue preparation and histochemistry 
Wild-type C57BL/6J and db/db/C57BL/6J mice were sacrificed following 
anaesthesia with intraperitoneal injection of a cocktail containing 65 mg/Kg ketamine 
and 13 mg/mL xylazine in sterile normal saline. The thoracic cavity was open and 
heart was removed. Then, the abdominal cavity was open and spleen was removed. 
Both harvested heart and spleen tissue were put in RNAlater RNA Stabilization 
Reagent (Qiagen, Cat # 76104) for further mRNA isolation. For 
immunohistochemistry, mice hearts were perfusion-fixed with 4% paraformaldehyde 
and 5% sucrose in PBS for 10 min, then embedded in optimal-cutting-temperature 
(OCT) compound, frozen on dry ice and stored at -70°C until sectioning. Serial 
7-µm-thick sections were obtained using a sliding criotome. For immunofluorescence 
staining, these sections were permeabilized, blocked for 30 min in phosphate-buffered 
saline (PBS) containing 1% BSA, and incubated for 1 h at 4°C with primary antibody 
against rabbit sarcomeric α-actinin cross-reacting with mouse. After washing with 
PBS, heart sections were incubated with FITC-conjugated antirabbit secondary 
antibody. The slides were washed, mounted and viewed through a fluorescence 
microscope.  
Heart sections were also prepared with H&E stain for structural analysis by 
light microscopy, with Sirius red stain to assess the presence and extent of fibrosis, 
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and with Oil Red O (ORO) to identify intramyocardial lipid deposition. The images of 
heart sections were obtained by digital camera and analyzed using the Metamorph 
Image System (Molecular Devices Corp., Downingtown, PA).  
12.5 RNA isolation and RT-PCR analysis  
RNA was isolated from mouse heart and spleen by using RNeasy mini kit as 
described above. First-strand cDNA synthesis was performed using iScript™ cDNA 
Synthesis Kit (Biorad, Cat # 1708890). The reaction system includes: 5 x iScript 
reaction mix 4 µl, iScript reverse transcriptase 1µl, RNA template 0.5 µg and 
Nuclease-free water to total volume 20 µl. Experiment was done following the 
reaction protocol: 5 minutes at 25°C, 30 minutes at 42°C, 5 minutes at 85°C. The 
specific aimed genes was analyzed using a panel of primers specific for 
mCD1(5’-AAGCTGGTCCCGCACAGA-3’ ， 3’- 
GCTGATGGTGGCTGAGTCATT-5’), TNFα 
(5’-TCGTAGCAAACCACCAAGTG-3’, 3’-AGATAGCAAATCGGCTGACG-5’), 
TNFα receptor1(5’-CCATCTTCGGTCCTAGTAACTG-3’, 
3’-CAGGTTCATCTTGGAAAGCAC-5’), TNFα receptor2 
(5’-GATGCCAAGGTGCCTCATG-3’, 3’-GAGCTGCTACAGACGTTCACG-5’). 
IQSYBR Green Supermmix (Biorad, Cat # 170-8880) was applied for 
semi-quantitative RT- PCR. And GAPDH was used for internal PCR control. The 
RT-PCR reaction system consists of 25 µl reaction buffer, 200nM final concentration 
of forward primer and reverse primer, 50ng cDNA and ddH2O to final volume 50 µl. 
Before semi-quantitation, the product annealing and melting curve were optimized. 
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Then Ct value is optimized by running with 3 minutes in a hot block at 95°C and then 
at 95°C (10 seconds), Tm°C (30 seconds) and 72°C (90 seconds) for 35 cycles. A 
series of sample dilutions were tested. Ideally the Ct value is linear between dilutions. 
With optimal Ct value and sample dilution the qRT-PCR reaction was done. 
12.6 Electrophoretic Mobility Shift Assays (EMSA)   
Nuclear proteins from wild-type C57BL/6J and db/db/C57BL/6J mice were 
extracted from snap-frozen hearts. Double-stranded NF-kB oligonucleotides (5’-AGT 
TGA GGG GAC TTT CCC AGG C-3’ and 5’-CCT GGG AAA GTC CCC TCA 
ACT-3’) (Promega, Madison, WI) were labeled with [γ-32P]ATP. Binding reactions 
containing 10 µg of crude nuclear extract were performed by using an EMSA core 
system (Promega, Cat # E3050) according to the manufacturer’s protocol. For 
supershift assays, goat monoclonal anti- p65 antibody (Santa Cruz, Cat # sc109) was 
used. 
12.7 Immunoblotting of p65 NF-κB subunits  
 An aliquot of the nuclear extracts used for EMSA and cytosolic or total 
extracts were loaded on 5-10% SDS-polyacrylamide gel electrophoresis under 
reducing conditions and was detected by Western-blotting method as described above. 
The following primary antibodies were applied: 1) polyclonal anti-rabbit p65 (Santa 
Cruz， Cat # sc101748); 2) anti-β-actin (Sigma Aldrich, Cat # A2547); 3) anti-lamin 
B (Santa Cruz, Cat # sc6217).  
13. Statistical Analysis   
All results are presented as means ± SD. Two-group comparisons were performed 
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with the use of a Student t-test for unpaired values. Multiple-group comparisons were 
made with analysis of variance (ANOVA).A p-value less than 0.05 was considered 
significant. Statistical analyses were carried out with the SPSS 15.0 version software 
Chicago IL.  
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Chapter 4 Results 
 
1. Prediction of lipid ligands for CD1d by computer stimulation 
The lipid profile in atherosclerotic plaque is complex and usually classified 
into three derivations: cholesterol, phospholipids and fatty acid. Under oxidative 
stress in the local environment they undergo oxidation modification and produce more 
pro-atherogenic compounds. To identify possible ligands among these pro-atherogenic 
compounds to CD1d, a molecular modeling program SYBYL was applied to screen 
the three groups of compounds. Their structures are input SYBYL program and 
binding capacity was displayed by score: higher binding capacity corresponds to 
higher score (Figure 11). The result showed that phospholipids and its oxidation 
derivatives have the highest binding affinity. Both fatty acid and cholesterol groups 
were weaker than the phospholipid group (Table 1). Based on these results, I selected 
PGPC, PAPC as my main target ligands in my experiments, 7-K-Cho, and cholesterol 
were used as control ligands. 
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Figure 11. Predicted CD1d capacity binding to three groups of lipids by running 
SYBYL program. A molecular modeling program SYBYL was applied to screen all 
these three groups of compounds. The structures of three groups of lipids and crystal 
structure of CD1 is input SYBYL program. The binding capacity was displayed by 
score: higher binding capacity corresponds to higher score.  
 
 
Lipid CD1d whole molecule 
 
Binding 
score 
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Star marked lipids chosen in the following experiments 
 
 
Table 1. Assessment of CD1d binding to three groups of lipids by computer 
molecular stimulation .  By using SYBYL program the binding capacity of three 
groups of lipids with CD1d was displayed by score: higher binding capacity 
corresponds to higher score. Among these groups of lipids, phospholipids and their 
oxidation derivatives have the highest binding capacity. Both fatty acid and 
cholesterol groups were weaker than the phospholipid group. 
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The binding capacity is mostly decided by crucial residues in CD1d since the 
hydrogen network is mainly accounted for the interaction between ligands binding to 
CD1d (Figure 12). The summary of these crucial residues in CD1d is displayed in 
table 2. Mouse and human CD1d are very similar in terms of structure and crucial 
binding sites. The only difference is tryptophan in human CD1d at position 153 and 
glycine at corresponding site in mouse. This difference does not influence ligand 
binding.   
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Figure 12.  Prediction of interaction between CD1d and lipid. The binding 
capacity is mostly decided by crucial residues in CD1d since the hydrogen network is 
mainly accounted for the interaction between ligands binding to CD1d.    
 
 
 
 
 
 
 
 
 
PGPC CD1d binding site 
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Table 2. Key binding sites between CD1d and lipids. Mouse and human CD1d 
share similar crucial binding sites in PGPC, PAPC and Chol.  
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2. Detection of lipids by GC/MS in murine plasma.  
          Based on the computer prediction results, GC/MS was applied for detecting 
the lipid levels in plasma of BALB/c mice. My results showed PAPC, PGPC, 7K 
and Chol can all be detected in the plasma of wild type (WT) BALB/c mice (Figure 
13). The presence of these lipids in mice plasma indicated the potential biological 
effect of these lipids in mice.  
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Figure 13. GC/MS analysis of presence of PGPC, PAPC, 7-K and Chol in the 
plasma of BALB/C mice  
By applying GC/MS the BALB/c mice plasma was analyzed, certain levels of PGPC, 
PAPC, 7K and Chol were all detected.  
 
 
 
 
PGPC 
7K Chol 
PAPC 
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3. Biology analysis of potential lipid ligands to CD1d by lipid binding assay 
Based on computer prediction results, biology analysis of these lipid ligands is 
further applied. As mentioned above, little difference exists between human and 
mouse CD1d in term of ligand binding theoretically. Our computer prediction results 
is in accordance. Therefore, in first part of the experiment, mouse CD1d was tested. 
Results showed that mCD1-HEK293 cells have higher 3H-7-K-Cho binding than 
untransfected HEK293 cells (Figure 14). Addition of excess PGPC but not cholesterol 
can inhibit 3H-7K-Cho binding in mCD1-HEK293 cells. These results are in liner 
with computer prediction results. Therefore, in further experiments I continued testing 
PGPC, PAPC as my main target ligands, 7-K-Cho and cholesterol were used as 
control ligands. 
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Figure 14. 3H-7-K-Cho binding to CD1d in the presence or absence of PGPC and 
free cholesterol. Results showed that CD1d transfected HEK293 cells have higher 
3H-7-K-Cho binding than untransfected HEK293 cells. Addition of excess PGPC but 
not cholesterol could inhibit 3H-7K-Cho binding in mCD1d stable cell lines.  
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4. CD1d-mediated lipid accumulation in spleen derived macrophages and CD1d 
transfect Hela cells (hCD1d-Hela) incubated with PGPC 
Lipid uptake and accumulation in mouse splenocytes were analyzed by 
fluorescence scanning confocal microscopy after staining with Nile Red, a 
lipid-binding fluorochome. The presence of hCD1d in hCD1d-Hela was proved by 
fluorescence observation and Western-blotting analysis (Figure 15). GFP was 
observed in both hCD1d-GFPN3 and GFPN3 plasmid transfected Hela cells. It 
indicates the successful transfection of plasmids into cells. By applying Anti-GFP 
antibody there was 72 KD protein detected in hCD1d-GFPN3 transfected Hela cells, 
while 34 KD protein was detected in GFPN3 transfected Hela cells. It indicated the 
presence of GFP in both transfected Hela cells. By applying anti-CD1d antibody there 
was still 72 KD protein detected in hCD1d-GFPN3 transfected Hela cells, while no 
protein was detected in GFPN3 transfected Hela cells. Therefore, hCD1d fused with 
GFP was successfully expressed in Hela cells. 
Under baseline conditions, without PGPC treatment, there was a weak signal 
for Nile Red staining in the cytoplasm of splenocytes (Figure 16a). However, when 
the cells were incubated with 4.8 µg/ml PGPC for 24 hours there was a substantial 
increase of Nile Red related fluorescence as visualized by fluorescence scanning 
confocal microscopy. The increased cellular Nile Red lipid stains existed not only in 
the cytoplasm of splenocytes incubated with PGPC, but also was patched on the 
cellular membrane (Figure 16b). Interestingly, the PGPC-associated lipid uptake and 
accumulation was diminished in the splenocytes of CD1-/- mice (Figure 16c). In Hela 
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cells transfected with hCD1d an increased level of cellular Nile Red lipid stains was 
observed when treated with 4.8 µg/ml PGPC. In Mock-Hela cells fewer stains was 
detected under confocal microscopy. The stains existed in both cytoplasm and the 
cellular membrane of PGPC treated hCDd-Hela cells, similarly to the distribution in 
splenocytes (Figures. 16d-f). The analysis of Nile Red intensity also showed higher 
level in PGPC treated CD1+/+ mouse splenocytes compared to untreated CD1+/+ 
mouse splenocytes, or treated CD1-/- mouse splenocytes (Figure. 16f). Thus, CD1 
expression contributes to the uptake and accumulation of PGPC. 
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Figure 15. Expression of hCD1d-GFP fusion protein in Hela cells transfected 
with hCD1d-GFPN3. a, b GFP was observed in both hCD1d-GFPN3 and GFPN3 
plasmid tranfected Hela cells. It indicates the successful transfection of plasmids into 
cells. c, d. By applying Anti-GFP antibody there was 72 KD protein detected in 
hCD1d-GFPN3 transfected Hela cells, while 34 KD protein was detected in GFPN3 
transfected Hela cells. It indicated the presence of GFP in both transfected Hela cells. 
By applying anti-CD1d antibody there was still 72 KD protein detected in 
hCD1d-GFPN3 transfected Hela cells, while no protein was detected in GFPN3 
transfected Hela cells. Therefore, hCD1d fused with GFP was successfully expressed 
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in Hela cells. 
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Figure 16. Nile Red fluorescence in CD1+/+ mouse splenocytes and 
hCD1d-Hela cells incubated with or without PGPC. A weak signal for Nile 
Red staining in the cytoplasm of splenocytes was detected (a). A substantial 
increase of Nile Red related fluorescence as visualized by fluorescence scanning 
confocal microscopy when cells were incubated with 4.8 µg/ml PGPC for 24 
hours. The increased cellular Nile Red lipid stains existed not only in the 
cytoplasm of splenocytes incubated with PGPC, but also was patched on the 
cellular membrane (b). Interestingly, the PGPC-associated lipid uptake and 
accumulation was diminished in the splenocytes of CD1-/- mice (c). In Hela 
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cells transfected with hCD1d an increased level of cellular Nile Red lipid stains 
was observed when treated with 4.8 µg/ml PGPC. In Mock-Hela cells fewer 
stains was detected under confocal microscopy. The stains existed in both 
cytoplasm and the cellular membrane of PGPC treated hCDd-Hela cells, 
similarly to the distribution in splenocytes (d-f). The analysis of Nile Red 
intensity also showed higher level in PGPC treated CD1+/+ mouse splenocytes 
compared to untreated CD1+/+ mouse splenocytes, or treated CD1-/- mouse 
splenocytes (a-c). 
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5. PGPC as a potential ligand for CD1d stimulating CD1d-restricted T cells 
5.1 Stimulation of mCD1d-restricted T cells by PGPC 
T0 specifically test PGPC as a ligand for CD1d, mCD1d transfected HEK293 
stable cells were used as APCs. The mCD1d stable cells were incubated with 
0-15µg/ml PGPC O/N then added to NKT hybridoma DN32.D3 cells. 
mCD1-HEK293 cells were loaded with lipid particals and “touching reaction” was 
observed between mCD1-HEK293 and DN32.D3 in both PGPC and 7-K-Cho treated 
groups. 3H thymidine was used for measuring the proliferation of NKT cells.  In 
mCD1-HEK293 cells high thymidine uptake occured in PGPC, PAPC and positive 
control α-GC stimulated groups (Figure 17a). Moreover, 15µg/ml PGPC and 15µg/ml 
PAPC groups showed higher stimulation compared to untransfected 293 cells (P<0.05, 
n=3) (Figure 17a). 
Cytokines secreted in the above assay were also detected. Both Th1/Th2 
cytokines (IL-4, IL-5, TNF-α, IFN-γ) were detected in all lipids treated cells after 24 
hours. PGPC, PAPC treated mCD1-HEK293 had higher cytokine secretion tendency 
compared with 7-K-Cho, Chol. My data show that the level of TNF-α was the highest, 
following by IFN-γ during all cytokines detected.  
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Figure 17. Comparison in thymidine incorporation between NKT hybridoma 
cells co-cultured with lipid treated 293 and mCD1-293. a. Measurement of 
proliferation of NKT cells stimulated by lipid treatment. In mCD1-HEK293 cells high 
thymidine uptake occured in PGPC, PAPC and positive control α-GC stimulated 
groups. Moreover, 15μg/ml PGPC and 15μg/ml PAPC showed higher stimulation 
compared to untransfected 293 cells (* P<0.05, n=3). Control group: Mock-293 cells; 
Vehicle: ethanol treated mCD1-293 cells.  
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5.2 Induction of CD1d expression in natural CD1d+ antigen presenting cells 
CD1d+ APCs in PBMCs include monocytes and macrophages. These cells 
have been proved certain CD1d expression. As a specific receptor for lipids, CD1d 
expression is assumed to be enhanced after treated with lipids. There is higher 
induction of CD1d in PAPC and PGPC treated PBMCs compared with 7-K-Cho and 
Chol groups (Figure 18). Positive control α-GC treated PBMCs showed induction of 
CD1d compared to control. Similar to PGPC, Hexadecyl Arachidonyl PC (HexPC) is 
one kind of oxidized PAPC, while HexPC group was not as high as the PGPC/PAPC 
group (Figure 18).  
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Figure 18. Western- Blotting assay for CD1d and GAPDH in lipid treated 
PBMCs. Higher induction of CD1d in PAPC and PGPC treated PBMCs compared 
with 7-K-Cho and Chol groups. Positive control α-GC treated PBMCs showed 
induction of CD1d compared to control. Similar to PGPC, HexPCgroup was not as 
high as the PGPC/PAPC group.  
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6. CD1d-mediated splenocytes responses to oxidized phospholipids  
      For identifying the role of CD1d in PGPC stimulated T cells reaction, WT 
BALB/c and CD1-/-BALB/c mice were used for this experiment. In BALB/c spleen 
cells the highest 3H thymidine uptake occured in PGPC, PAPC and positive control 
α-GC stimulated groups (Figure 19a). BALB/c spleen cells had the highest thymidine 
uptake when stimulated with 7.5µg/ml PGPC, 3.75µg/ml PAPC, while in the CD1-/- 
BALB/c group this effect was not observed (Figure 19b). 
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Figure 19. Comparison in thymidine incorporation between CD1-/- BALB/C and 
BALB/C splenocytes. a. Measurement of proliferation of splenic cells stimulated by 
lipid treatment. In BALB/c spleen cells the highest 3H thymidine uptake occured in 
PGPC, PAPC and positive control α-GC stimulated groups. b. BALB/c spleen cells 
had the highest thymidine uptake when stimulated with 7.5μg/ml PGPC, 3.75μg/ml 
PAPC, while in CD1-/- BALB/c group this effect was not observed. (n=3, * p<0.05）  
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In order to observe the immune response of PGPC in vitro, spleen cells from 
BALB/c mice, as well as CD1-/- mice were stimulated with different concentrations 
of PGPC. Proliferation of spleen cells was dose-dependent, in corresponding to range 
from 0 µg/ml to 9.6 µg/ml. The optimal stimulation dose was 4.8 µg/ml. However, 
there was no significant proliferation index observed in CD1-/- spleen cells group 
(Figure 20a). The production of IFN-γ showed the same tendency (Figure 20b). For 
PAPC there were no significant difference of proliferation and IFN-γ production 
observed between CD1+/+ and CD1-/- spleen cells (Figure 20a, b). 
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Figure 20. The response of PGPC was CD1d mediated. PGPC and PAPC were 
used to stimulate spleen cells from BALB/c and mCD1d-deficient mice in vitro. Fresh 
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splenic cells from BALB/c or CD1-/-BALB/c 4x105 were plated in 96-well plate and 
pulsed with 0.3-9.6μg/ml PGPC/PAPC. a, b. After 72 hours of culture, spleen cell 
proliferation was measured (n=4). c, d. After 48 hours of culture, supernatants were 
collected and IFN-γ production was measured (n=2). (* p<0.05）  
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7. Detection of cell type producing IFN-γ stimulated with PGPC 
To further identify IFN-γ secreting cells, we treated BALB/c spleen cells with 
4.8µg/ml PGPC for 24 hours and stained these cells with anti-IFN-γ-Alexa647 and 
anti-CD3-FITC antibodies. The IFN-γ secreting cell group was mostly detected in 
CD3+ positive cells in both α–GC and PGPC treated cells (Figure 21 a). 
Approximately 1.43 ± 0.17% (n=3) of the CD3 positive cells were secreting IFN-γ 
after PGPC treatment. In contrast, only 0.24 ± 0.06% (n=3) of the cells secreting 
IFN-γ were detected in the vehicle group (Figure 21 b). Only 0.38 ± 0.31 % (n=3) of 
CD3 negative cells produced IFN-γ after PGPC treatment. When CD3 negative cells 
was treated with α–GC, only 0.33 ± 0.13% (n=3) of IFN-γ secreting cells were 
detected. 
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Figure 21. Responder T cells in lipid treated BALB/c spleen cells. 107 BALB/c 
spleen cells were treated with 4.8μg/ml PGPC and collected for FACS analysis after 
24 hours. Anti-IFN-γ-Alexa647 and anti-CD3-FITC antibodies were applied for 
double staining after cells were fixed by 4% formaldehyde and permeabilized with 
90% methanol.  a. Q2 percentage stands for the percentage of IFN-γ secreting cells 
in CD3+ cells.  b. The positive IFN-γ secreting cells were analyzed and compared 
between CD3+ and CD3- cells. 
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8. Presence of PGPC reacting CD1-restricted T cells in ApoE-/- mice and WT 
mice 
To examine the population of reactive NKT cells in mouse, we stained spleen 
cells from ApoE-/- C57BL/6J and WTC57BL/6J with PGPC-loaded 
mCD1d-tetramers. There was clear staining of CD3+ cells stained by PGPC-loaded 
mCD1d-tetramers. In spleen cells from WT mice only 0.9 ± 0.3% (n=3) (Figure 22, 
Q2) of the T cells were stained with PGPC-loaded mCD1d tetramers, and 0.9 ± 0.23% 
of T cells stained with PGPC-loaded mCD1d tetramers was found in ApoE-/- mice 
spleen cells (n=3)  
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. 
 
 
 
 
Figure 22. Flow cytometry of CD1d-tetramers loaded with PGPC stained CD3+T 
cells. CD1d-tetramers loaded with PBS-57 (+), unloaded CD1d-tetramer (-) were also 
used as controls to stain ApoE-/- and C57BL/6J spleen cells. Numbers in the quadrant 
correspond to percent cells out of total CD3+ cells and data shown are gated live cells 
(n=3). 
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9. Analysis of TCR repertoire 
To further characterize the responder T cells to PGPC, we sorted CD3 and 
CD1d tetramer double positive cells from ApoE-/- CD57BL/6 and WT CD57BL/6 
mouse spleen cells and applied RT-PCR to analyze T cell receptor repertoire.  Our 
results revealed these sorted cells are Vα14, Jα281 positive for mouse T receptor 
(Figure 23). These data showed that PGPC reacted T cells are TCR Vα14, Jα281 NKT 
subgroup in mouse. 
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Figure 23. RT-PCR analysis of TCR repertoire in ApoE-/- and WT C57BL/6J 
mice.  ApoE-/- C57BL/6J and WT C57BL/6J mouse spleen cells were stained with 
PGPC loaded mouse CD1d-tetramer and mCD3. Double positive cells were collected 
by flow cytometry sorting and total RNA was extracted and analyzed by RT-PCR by  
using Vα14.2, Jα281 primer pairs. GAPDH was used as a control. Negative control: 
murine embroynic stem cells. 
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10. Development of hyperlipidemia and hyperglycemia in db/db mice  
      To testify the lipid level in the db/db mouse model, fresh blood was used for 
analysis of lipid profile and glucose level. Results are shown in Table 3. There was 
significant body weight (BW) (P<0.01, n=3) and heart weight (HW) (P<0.05, n=3) 
increase in db/db compared to WT. All lipid levels increased in db/db compared to 
WT, among triglyceride at very high level 769±206 (n=3). LDL, cholesterol and 
VLDL in db/db mice also increased significantly compared to WT (P<0.01, n=3). 
Therefore, hyperlipidemia exists in db/db mouse model.  
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Table 3. Lipid profiles and glucose levels in serum of db/db C57BL/6J and 
C57BL/6JJ mice. There was significant body weight (BW) (P<0.01, n=3) and heart 
weight (HW) (P<0.05, n=3) increase in db/db compared to WT. All lipid levels were 
increased in db/db compared to WT among triglyceride at very high level 769±206 
(n=3). LDL, cholesterol and VLDL in db/db mice also increased significantly 
compared to WT (P<0.01, n=3). 
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11. Different expression of CD1d between db/db and C57BL6 spleen cells  
      CD1 expression on db/db C57BL6 and WT C57BL6 spleen was detected by 
anti-mCD1 mAb conjugated with PE as shown in Figure 24a, b. The analysis revealed 
higher level of CD1 expression in spleen of 2 months old db/db mice (56.9± 2.3%, 
n=3) compared to WT mice (42.8± 5.8%, n=3), not observed in spleen of 12 months 
old mice. Interestingly, the CD1 expression was found decreased in 12 months old 
db/db mice spleen (45.8± 6.6%, n=3) compared to 2 months old db/db mice. In 
addition, we observed CD1 mRNA level on db/db and WT mice spleen. As shown in 
Figure 24c, there is 1.34 fold increased CD1 mRNA expression in db/db mice spleen 
after normalization with GAPDH.  
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Figure 24. Comparsion of CD1 expression in spleens of db/db and WT mice. The 
analysis revealed higher level of CD1 expression in spleen cells of 2 months old db/db 
mice (56.9± 2.3%, n=3) compared to WT mice (42.8± 5.8%, n=3), which is not 
observed in spleen cells of 12 months old mice. Interestingly the CD1 expression was 
found decreased in 12 months old db/db spleen cells (45.8± 6.6%, n=3) compared to 2 
months old db/db mice. In addition, we observed CD1 mRNA level on db/db and WT 
spleen cells. As shown in figure 23 (c), there is 1.34 fold increased CD1 mRNA 
expression in db/db spleen cells after normalization with GAPDH. * p<0.05, n=3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
94 
12. Increased TNFα expression in db/db spleen cells and TNFα receptor1 in 
cardiac cells 
The TNFα mRNA expression in db/db spleen cells was detected by 
quantitative RT-PCR and showed 6 folds increase of TNFα expression in db/db spleen 
cells compared to WT spleen cells (Figure 25a). We further detected TNFα receptor1 
and TNFα receptor2 mRNA expression in cardiac cells of db/db and WT mice. Only 
TNFα receptor1 mRNA had 4.89 folds increase in db/db cardiac cells compared to 
WT (Figure 25b), no significant TNFα receptor2 mRNA expression difference was 
found between db/db and WT cardiac cells.  
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Fig 25. Expression of TNFαin db/db and WT spleen and TNFαR1 in db/db and 
WT heart. The TNFα mRNA expression in db/db spleen cells was detected by 
quantitative RT-PCR and showed 6 folds of increased TNFα expression in db/db 
spleen cells compared to WT spleen cells (a). We further detected TNFα receptor1 and 
TNFα receptor2 mRNA expression in cardiac cells of db/db and WT mice. Only 
TNFα receptor1 mRNA had 4.89 folds increase in db/db cardiac heart tissue 
compared to WT (b). No significant TNFα receptor2 mRNA expression difference 
was found between db/db and WT cardiac cells.  
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13. Lipid accumulation and NF-kB activity in hearts of db/db mice. 
Insulin resistance is frequently associated with lipid deposition in nonadipose 
tissue. Db/db mice showed significantly larger fatty liver and lipid accumulation in 
hearts (Figure. 26a) compared with C57BL/6J mice (Figure. 26e). In the db/db mice 
there was no apparent cardiac hypertrophy (Figure 26b) or fibrosis (Figure. 26d) 
compared with C57BL/6J mice (Figure. 26f and h).  Immunofluorescence staining 
for sarcomeric markers such as α-sarcomeric actinin (a crucial Z-disc protein that 
cross-links sarcomeric actin) revealed sarcomeric integrity with the absence of cardiac 
anomalies including loss of muscle striation or pathological myofibre disarray in the 
diabetic hearts (Figure. 26c) as well as C57BL/6J mice (Figure. 26g).  
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Figure 26. Histochemistry of heart sections from db/db and WT mice. db/db mice 
showed significantly larger fatty liver and lipid accumulation in hearts (a) compared 
with C57BL/6J mice (e). In the db/db mice there was no apparent cardiac hypertrophy 
(b) or fibrosis observed (d) compared with C57BL/6J mice (f and h).  
Immunofluorescence staining for sarcomeric markers such as α-sarcomeric actinin (a 
crucial Z-disc protein that cross-links sarcomeric actin) revealed sarcomeric integrity 
with the absence of cardiac anomalies including loss of muscle striation or 
pathological myofibre disarray in the diabetic hearts (c) as well as C57BL/6J mice 
(g).  
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The nuclear transcription factor NF-κB binds to the promoter critical for the 
transcription of many proinflammatory genes. We examined the expression and 
activation of NF-κB in the hearts of adipose diabetic (db/db) and nondiabetic control 
mice, by using the gel shift assay with a with a 32P end-labeled NF-κB oligonucleotide. 
The nuclear proteins were isolated from nitrogen snap-frozen hearts and subjected to 
EMSA for NF-kB activity. As shown in Figure. 28 a, NF-kB binding activity is low in 
age-matched normal hearts but significantly increased in db/db hearts (Figure 27a, 
lanes 1-4 vs. 5-8).  The specificity of the NF-κB DNA protein complex formation 
was verified by cold oligonucleotides and by the addition of anti-p65 NF-κB antibody 
which super-shifted the bands of NF-κB/DNA complexes (lanes 1, 3, 5, 7). Antibody 
to p65/RelA was capable of supershifting a portion of the protein binding to the DNA, 
indicating the involvement of, but not limited to p65 subunit in the activation of 
NF-kB transcriptional in the db/db hearts. There was no significant binding with the 
oligonucleotide probe alone or by omitting protein substrate. Levels of p65 subunit 
were determined by Western blot in db/db in comparison with their respective 
background wild-type C57BL/6J. Nuclear levels of p65 in db/db mice and nondiabetic 
C57BL/6J control mice reflected the NF-kB binding activity data (Figure 27b). The 
total protein content of NF-κB p65 (Figure 27b) subunit was similar in hearts from 
db/db mice and nondiabetic C57BL/6J controls. Interestingly, immunoblotting 
demonstrated decreased nuclear accumulation of NF-κB p65 subunit in the hearts of 
CD1d-knockout compared with control mice (Figure 27c). The presence of NF-κB 
p65 subunit was highly detectable in cytosolic extracts from CD1d-knockout mice 
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(Figure 27c), indicating the lack of cytosolic-nuclear redistribution of p65 and 
therefore no activation of canonical NF-κB in the absence of CD1d. 
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Figure 27. NF-κB activity in hearts of db/db mice. As shown in Figure. 28 a, 
NF-kB binding activity is low in age-matched normal hearts but significantly 
increased in db/db hearts (lanes 1-4 vs. 5-8).  The specificity of the NF-κB DNA 
protein complex formation was verified by cold oligonucleotides and by the addition 
of anti-p65 NF-κB antibody which super-shifted the bands of NF-κB/DNA complexes 
(lanes 1, 3, 5, 7). There was no significant binding with the oligonucleotide probe 
alone or by omitting protein substrate. Levels of p65 subunit were determined by 
Western blot in db/db in comparison with their respective background wild-type 
C57BL/6J. Nuclear levels of p65 in db/db mice and nondiabetic C57BL/6J control 
mice reflected the NF-kB binding activity data (b). The total protein content of NF-κB 
p65 (b) subunit was similar in hearts from db/db mice and nondiabetic C57BL/6J 
controls. The immunoblotting demonstrated decreased nuclear accumulation of 
NF-κB p65 subunit in the hearts of CD1d-knockout compared with control mice and 
NF-κB p65 subunit was highly detectable in cytosolic extracts from CD1d-knockout 
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mice (Figure 27c). 
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                       Chapter 5: Discussion 
1. Identification of ligands for CD1d related in atherosclerosis 
      My study has identified PGPC as a novel lipid autoantigen recognized by 
CD1-restricted T cells. As atherosclerosis is considered as inflammation, my finding 
revealed that atherosclerosis is an autoimmune disease. The lipid components in 
atherosclerotic plaque are complexe. SYBYL program filters the lipid component as 
possible ligands for CD1d. In recent years, increasing numbers of ligands of CD1d 
have been studied. Most studies were based on individual analysis and testing. The 
screening method by applying SYBYL is novel in terms of exploring CD1d ligands. 
This method is repeatable, low cost and in line with biological results, which was 
proved through biological experiment results. Although this software analysis is 
theoretical, the needs for biological tests are requested. For CD1d, hydrogen bond is 
the main force between ligand and CD1d binding site. Therefore, my analysis is 
mainly based on hydrogen bond analysis, which neglects other interaction forces. To 
some extent, this method is not appropriate for comparing the capacity of similar 
ligands. In my study, PAPC and its oxidative product PGPC showed very close 
binding score. They were both tested in later biological experiments. 
Among the three groups of lipids phospholipids, fatty acid and cholesterol and 
their oxidation products, phospholipids and its oxidative phospholipids has shown 
highest binding capability to CD1d followed by arachidonic acid group and the 
cholesterol group. Phospholipids are the main component of cell membrane and 
circulating LDL. In atherosclerosis, phospholipids are prone to be oxidized under the 
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oxidative stress. My findings revealed high possibility of phospholids and oxidative 
phospholipids as ligands for CD1d. In atheroma there is high level of detected 
oxysterols. High cholesterol in the blood stream is the main risk for developing 
atherosclerosis. When cholesterol is deposited and modified by oxidative stress, it 
becomes the target of local APCs like DCs and SMC. The expression of CD1d on 
these APCs indicates that oxysterols could be ligands for CD1d in athersoclerosis. 
Nonetheless, my results showed very low binding capacity of CD1d to this group of 
lipids. Past studies have found that cluster of differentiation 36 (CD36) could be the 
main receptor for oxysterols.  
Fatty acid and its oxidation products also exist in atherosclerotic plaque. In 
contrast to OxPLs and oxysterols, oxidized fatty acids play less important role in 
atherosclerosis development due to their low amount and weaker atherogenic role. 
The binding score showed comparatively lower binding strength between CD1d and 
this group of lipids. Hence, OxPLs are strong candidates as ligands for CD1d in 
atherosclerosis according to SYBYL program predicted results. 
In terms of the receptors related to phospholipids, several ligands have been 
found to be involved in binding to OxPLs. The scavenger receptor CD36 has been 
identified as a receptor for OxPAPC. CD36 is mainly expressed on monocytes, 
platelets and erythrocytes in vessels. Oxidized lipids mainly locate in atherosclerotic 
plaque, where main CD36 positive cells are SMCs. SMCs turns into foam cells after 
uptaking oxidized lipids. OxPLs could be the potential ligand for CD36 expressed on 
SMCs in late stage of atherosclerosis. Another potential receptor TLR can be detected 
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on monocytes/macrophages and DCs. In atherosclerotic plaques TLR1, 2, 4 have been 
detected in both human and mice samples, and induced by IL-1 (58). Hence, there is 
possibility that OxPLs are presented by TLR and contribute to the development of 
atherosclerosis.  
My results also showed a close binding score between hCD1d and mCD1 in 
most lipids. The structures of human CD1d and mouse CD1 are very similar. The only 
difference is that tryptophan at position 153 in human isoform is replaced by glycine 
155, which does not affect binding capability. Previous studies showed that mouse 
CD1 can activate human CD1d-restricted T cells and vise versa. Therefore, my results 
are consistent with previous studies.  
The phospholipid PAPC oxidation products are the main components 
activating endothelial-monocyte interaction in MM-LDL (49, 88). When human aortic 
endothelial cells (HAECs) were treated with OxPAPC an IL-8 synthesis was observed. 
This cytokine is one of the main signals for monocyte transmission into vessels (60). 
In atherosclerotic plaques, accumulated PAPC oxidation derivatives can be detected. 
Pidkovka and co-workers found that OxPAPC can cause phenotypic switching of 
SMCs and contribute to the progression of atherosclerosis (89, 90). Earlier reports 
have indicated that apoptotic cells contain higher level of PAPC oxidation derivatives 
(91). The apoptotic cells attract more monocytes and lymphocytes leading to an 
“inflammation burst”.  Furthermore, the retained OxPLs can activate platelets and 
cause thrombosis, which is a crucial step in the progression of atherosclerosis (62). 
The PAPC oxidation product, PGPC is an effective component of OxLDL causing 
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atherosclerotic plaque. During atherosclerosis progression, apoptotic cells become 
another origin for PGPC. Previous studies have suggested that CD1d-restricted T cells 
aggravate atherosclerosis in the mouse model. The natural antigens presented by 
CD1d to T cells are critical in atherosclerosis progression and new therapeutic targets 
can be explored based on identified natural antigens.  
As mentioned above there are several lipid transporters responsible for the 
translocation through the lipid bilayer. My data shows that there is an increased level 
of PGPC uptaken by CD1+/+ mouse spleen cells compared to CD1-/- (Figure 3). Also, 
CD1d transfected Hela cells showed an increased uptake of PGPC compared to mock 
Hela cells. These data suggested that CD1d functions as an important transporter for 
PGPC into the cells. 
Based on computer prediction and GC/MS analysis of lipids in BALB/c mice 
plasma, PAPC and PGPC were further tested on HEK293 stably expressing mCD1. 
There is higher 3H-7-K-Cho binding in mCD1d stably expressed HEK293 compared 
to HEK293. The CD1d expression is very low in untransfectted HEK293. The high 
binding of 3H-7-K-Cho that occurred in mCD1d-HEK293 indicates an important role 
of CD1d in lipid binding. Since the binding assay was carried out in cold temperature, 
lipid uptake effect is mostly blocked due to “low mutability” of the cell membrane. 
The binding effect was observed in the greatest extent. Therefore, even low score has 
been predicted by molecular modeling analysis，the binding between CD1d and 
3H-7-K-Cho was observed in my experiments.  When PGPC was added into 
mCD1d-HEK293 before 3H-7-K-Cho, there was very low binding of 3H-7-K-Cho 
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detected. I presumed that PGPC has stronger binding capacity with CD1d than 
7-K-Cho. In contrast, the addition of Chol before 3H-7-K-Cho can not block the 
binding of 3H-7-K-Cho to CD1d. As predicted by SYBYL, the binding score of Chol 
with CD1d was very low. Over all, the lipid binding assay further proved that PGPC 
is a possible ligand for CD1d.  
      When lipid is presented by CD1d to CD1d-restricted T cells, T cells are 
activated and release cytokines. The activation of T cells can be measured by 
thymidine uptake. The incorporation of thymidine mainly reflects the proliferation of 
T cells as thymidine is the material for synthesizing DNA.  We used mCD1-HEK293 
as APCs and treated with lipids for O/N. Then DN32.D3 was used as effector T cells 
and co-cultured with lipid treated mCD1-HEK293. 
 Thymidine uptake assay results demonstrated that high thymidine uptake 
occurred in PGPC, PAPC and positive control α-GC treated mCD1-HEK293 cells. 
When comparing to untransfected HEK293, 15µg/ml PGPC and 15µg/ml PAPC 
treated mCD1-HEK293 groups showed higher stimulation. This further proved the 
important role of CD1d in stimulating CD1d-restricted T cells. Compared to 7-K-Cho 
and cholesterol, PGPC and PAPC are stronger in stimulating T cells, consistent with 
lipid binding results. Only 100 ng/ml α-GC is enough to stimulate CD1d-restricetd T 
cells, while 15µg/ml PGPC or 15µg/ml PAPC is needed for the highest stimulation of 
T cells. The ligand α-GC is derived from marine sponge and does not exist in human 
body. It is mostly synthesized and has a very specific binding effect to CD1d. PGPC is 
found mainly in atherosclerotic plaques; therefore most likely contribute to activate T 
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cells, leading to atherosclerosis. 
Besides the thymidine uptake assay, the measurement of cytokine secretion 
provides proof of activation of T cells. My results showed very low secretion of 
cytokines including IL-4, IL-5, IFN-γ and TNF-α in all lipids treated HEK293. In 
lipids treated mCD1-HEK293, PGPC, PAPC and 7-K-Cho all above four cytokines 
have been detected with TNF-α as the highest, followed by IFN-γ, IL-5 and IL-4. 
PGPC and PAPC treated groups had higher cytokines secretion than 7-K-Cho. This 
result further proved the strong effect of PGPC and PAPC in activating 
CD1d-restricted T cells. The higher secretion of IFN-γ and TNF-α means the 
inflammatory effect is the main consequence of T cell activation.  
Since PAPC and PGPC have been found as strong ligands for CD1d, the 
induction of CD1d by this group of lipids further proved a possible amplification 
effect.  Western blot results showed stronger induction of CD1d protein in PGPC, 
PAPC and HexPC treated PBMCs compared to 7-K-Cho and Chol treated PBMCs. 
The induction of CD1d may exemplify the ligand-CD1d presentation effect and 
activate more CD1d-restricte T cells. Due to mixed cell components in PBMCs, no 
exact cell types were identified as induced cell origin. It is postulated that CD1d 
positive APCs are the main cell sources for the enhanced CD1d. 
       
2. CD1d mediated immune reactions in atherosclerosis 
      NKT hydrioman DN32.D3 can be activated by phospholipids treated 
mCD1d-HEK293 as proved by cell proliferation and cytokine secretion. As CD1d is 
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transfected into HEK293, the role of CD1d observed is magnified and PGPC as a 
ligand of CD1d may be amplified. In order to further prove the PGPC ligand effect 
and test that PGPC caused T cell activation is CD1d medicated, CD1-/- was applied in 
a series of experiments.  
In the measurement of proliferation of WT and CD1-/- splenic cells in 
response to lipid treatments by thymidine uptake assay, only α-GC, PGPC and PAPC 
groups had strong proliferation at both concentrations of 3.75 µg/ml and 7.5 µg/ml 
(Figure18). In α-GC group, 3.75µg/ml is enough to get highest stimulation of splenic 
cells, while in PGPC group, 7.5µg/ml had higher stimulation than 3.75µg/ml. This 
result is consistent with previous mCD1-HEK293 thymidine uptake results. PAPC 
group was not observed as strong stimulation as PGPC, which is consistent with 
previous results.  
In addition to measuring the proliferation by thymidine uptake assay, cell 
proliferation was also measured using Quick cell proliferation assay. This assay is 
based on the cleavage of the tetrazolium salt to formazan by cellular mitochondrial 
dehydrogenase. Therefore, the dye generated by this cleavage is directly proportional 
to the number of live cells. The result also showed robust response of BALB/c mouse 
spleen cells to PGPC, which indicated that PGPC acts as an important antigen for T 
cells. The absence of response in CD1-/- mouse spleen cells treated with PGPC 
further implies that the effect is CD1d dependent. Currently, two families of self 
antigens have been known to stimulate T cells: sphingolipids and phospholipids (92). 
Gumperz et al found that murine CD1d-restricted T cells recognize cellular lipids (47). 
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Our results are consistent with these results. Moreover, we identified the lipid 
autoantigen presented by CD1d related to atherosclerosis. In my experiment, the 
WTBALB/c splenic cells responded to PGPC dose dependently (0.3-9.6µg/ml), 
among which the highest splenic cell proliferation occurred at 4.8µg/ml. The optimal 
PGPC stimulation concentration is lower in WT splenic cells (4.8µg/ml) than 
mCD1-HEK293 (7.5µg/ml). This can be partially explained by highly expressed 
CD1d in mCD1-HEK293 than WT splenic cells, since the former is mCD1d fully 
expressed and the latter is mixed cells with only percentage cells expressing mCD1d. 
We observed only a minor effect of PAPC in causing murine T cells proliferation 
similar to above results.  
I demonstrated that PGPC not only can induce proliferation of mouse spleen 
cells, but it also stimulated cytokine secretion. In PAPC treated splenic cells, there 
was low level of IFN-γ production, suggesting that OxPLs may mediate inflammatory 
effects occurred in atherosclerotic plaques. It is consistent with a previous study in 
which Melian et al found the increased expression of CD1d in human atherosclerotic 
plaques (25). Moreover, Yeh et al has indicated that PAPC has no effect in the 
induction of IL-8 in both human aortic endothelial cells and Hela cells. Other reports 
indicate that iNKT can cause plaque neovascularization and destabilization in human 
atherosclerosis by releasing IL-8 (93, 94). We did not measure IL-8, a potential 
cytokine associated with atherosclerosis, but we will consider measuring it in a future 
study. Chiappori et al found that a phospholipid [phosphatidylethanolamine (PTY)] is 
a ligand for endothelial protein C receptor (EPCR), a CD1-like transmembrane 
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glycoprotein regulating protein C (PC) pathway and produces anticoagulant, 
anti-inflammatory, and anti-apoptotic effects (95). These reports, together with our 
data, suggest that PGPC may act as a ligand for EPCR and induce inflammatory effect 
similar to CD1d. 
There are several lipid transporters responsible for the translocation through 
the lipid bilayer. We show that there is an increased level of PGPC that is taken in by 
CD1+/+ mouse spleens cells compared to CD1-/-. Also, CD1d transfected Hela cells 
showed an increased uptake of PGPC compared to mock Hela cells. These data 
suggest that CD1d functions as an important transporter for PGPC into the cells. 
Furthermore, we detected that the IFN-γ secreting cells consisted mainly of T cells. 
Effector T cells secret inflammatory molecules and directly contribute to the 
progression of atherosclerosis. IFN-γ secreted by T cells after stimulated with PGPC 
revealed the pathological significance of PGPC related to atherosclerosis. It is also 
interesting that a robust IFN-γ secretion was observed when cells were treated with 
1.2 µg/ml of PGPC. The earlier detection of IFN-γ compared to proliferation may be 
due to method sensitivity, or that IFN-γ signaling precedes the response of PGPC 
stimulation.  
T cells are usually considered as effector cells for antigens presented by CD1d. 
CD3 is part of TCR on mature T cells. Therefore, anti CD3 antibody was applied in 
order to identify if T cells are IFN-γ secreting cells. The result showed higher double 
staining of CD3 and IFN-γ in both α-GC and PGPC groups than PAPC (Figure 20 a, 
b). This result further proved T cells produced IFN-γ in response to α-GC and PGPC. 
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The analysis of IFN-γ secreting cells found that T cells are the main group of cells in 
secreting IFN-γ (Figure 20 c) in both α-GC and PGPC groups. 
To prove the existence of PGPC reacting T cells in vivo, we investigated the 
PGPC-loaded mCD1d tetramer stained with both ApoE-/- and WT mice spleen cells. 
Previous studies have demonstrated that the specific ligands recognized by CD1d can 
be analyzed by applying ligand-loaded CD1d tetramer staining (96, 97). Our results 
showed that the PGPC-loaded mCD1d tetramer binds CD3+ cells. Also, our data 
suggest that PGPC reacted T cells exist in murine spleen cells. Since there is no 
significant difference in the percentage of PGPC reacted T cells between ApoE-/- and 
WT spleen cells, I therefore postulate that endogenous PGPC-loaded T cells may exist 
in ApoE-/- spleen cells, but they were not detected by our exogenous PGPC loaded 
method.  
Furthermore, we characterized the receptor of this group of T cells. It is 
consistent with previous murine studies in which the universal recognition of lipids 
occurs through Vα14, Jα281 NKT cells (98). It has been found that phospholipids can 
stimulate the regulatory function of human Vα24β11 NKT cells (99), a group of 
autoreactive T cells homologous to mouse Vα14, Jα281 NKT cells.  
We investigated the activation of T cells by PGPC in a murine system. We also 
demonstrated the presence of PGPC-reacting T cells in blood samples from 
atherosclerotic patients in which further studies will be conducted. However, our 
investigation did not study the process of PGPC in cells and exact presentation of 
PGPC by CD1d. Barral’s study showed that CD169(+) macrophages can internalize 
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and present lipid antigens to NKT cells in CD1d-dependent manner (100). However, 
little information is available describing how this process occurs in CD1d-positive 
antigen presented to PGPC in cells. We found the PGPC responder T cells were Vα14, 
Jα281 NKT cells. Nonetheless, we cannot rule out that other populations of T cells 
may be involved in PGPC activation.  
 
3. CD1d expression and impact on heart injured by hyperlipdemia 
3.1 CD1d-mediated NF-κB signaling 
In the db/db mouse model, there is noticeably different lipid profile measured 
in the blood compared to WTC57BL/6J. The lipid components are consisting of LDL, 
VLDL, triglyceride, cholesterol and HDL. As anticipated there were increased LDL, 
VLDL, triglyceride, and cholesterol in db/db peripheral blood in contrast to WT 
peripheral blood. Triglyceride was the highest increased group among above four lipid 
groups. The increased lipid level is critical factor causing atherosclerosis. Although no 
atherosclerosis plaques were noticed in observed db/db samples, the high triglyceride 
level implicated the high risk of atherogenesis in this mouse model. Since no obvious 
atherosclerotic plaque was observed, no oxLDL was able to be detected locally like in 
aorta. 
The induction of CD1d by lipids was detected, which is similar to inducing 
CD1d in lipids treated PBMCs. In mouse spleen is the main organ holding many types 
of immune cells including CD1d expression cells and CD1d responder cells. 
Considering high levels of LDL in db/db peripheral blood, the speculation that CD1d 
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can be induced in spleen in this type of mouse was tested. In 2-months-old, higher 
expression (56.9± 2.3%, n=2) was detected compared to WT mice (42.8± 5.8%, n=2) 
by FACS. There was a 1.34 fold increase in CD1 mRNA expression in db/db spleen 
cells after being normalized with GAPDH. The FACS result is similar to RT-PCR 
result and both indicated the possible induction of CD1d by high LDL as detected in 
db/db peripheral blood. FACS only detected the CD1d protein expressed on cell 
surface, which may partially explain the less detected CD1d compared to total CD1d 
mRNA. In 12-month-old mice this tendency was not observed. The reduced 
expression of CD1d in older mice may implicate that CD1d expression can be 
reduced after long exposure to hyperlipidmia, a characteristic of db/db mice. Type 2 
diabetes is considered as a chronic inflammatory disease with circulating 
proinflammatory factors like TNFα and interleukin-1 (IL-1). It has been reported that 
the population of NKT cells was reduced in high fat fed mice (Miyazaki et al). 
Therefore, the exposure to the high fat environment may lead to suppressed CD1d and 
further NKT cells consequently. This reduces CD1d and suppressed NKT cell 
expression, likely results in chronic inflammation, which can re-affect the 
inflammation development.  
3.2 CD1d induced inflammation in atherosclerosis and NF-κB activation 
Db/db mice showed significant larger fatty liver and lipid accumulation in 
hearts compared with C57BL/6J mice. In the db/db mice, there was no apparent 
cardiac hypertrophy or fibrosis observed compared with C57BL/6J mice. 
Immunofluorescence staining for sarcomeric markers such as α-sarcomeric actinin (a 
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crucial Z-disc protein that cross-links sarcomeric actin) revealed sarcomeric integrity 
with the absence of cardiac anomalies including loss of muscle striation or 
pathological myofibre disarray in the diabetic hearts (Madonna Rosalinda, Hanjing 
Wu, Yong-jiang Geng. Cardiac expression and activation of NF-kB in association 
with enhanced spleen inflammation in mice with obesity and diabetes, in preparation). 
With previous findings that TNFα can be secreted by activated CD1d-restricted T 
cells originating from the spleen, further inflammatory effects from the spleen was 
detected. There was 6 folds of increased TNFα expression in db/db spleen cells 
compared to WT spleen cells. Moreover, in correspondence to the increased TNFα 
expression in spleen, there was a 4.89 folds of increased TNFα receptor1 mRNA in 
db/db heart compared to WT. TNFα receptor1 is the main TNFα receptor in the 
murine heart. Accordingly, elevated TNFα receptor1 is most likely the consequence of 
increased TNFα in spleen. Hence the heart changes that occurred in db/db mice are 
more likely from the Para-endocrine factors from the spleen. 
As nuclear NF-κB was found activated and increased in the heart of db/db 
mice compared to WT (Madonna Rosalinda, Hanjing Wu, Yong-jiang Geng. Cardiac 
expression and activation of NF-κB in association with enhanced spleen inflammation 
in mice with obesity and diabetes, in preparation), TNFα is considered as a factor 
contributing to an upstream signal. There are several pathways that can activate 
NF-κB. My observation indicated possible activation from spleen. Due to limited 
inflammation observed in the heart, the outer inflammatory stimulator is highly 
possible. The inflammatory effect from the spleen can not exclude other factors 
  
117 
contributing to the production of NF-κB in the heart. More studies including human 
studies are needed to examine this inflammatory effect.  
In summary, we identified a new self-antigen that can activate murine spleen T 
cells. Our current data support the idea that PGPC acts as an antigen in the activation 
of CD1d-restricted T cells. Considering the existence of an elevated PGPC level in 
atherosclerotic plaques, we suggest that PGPC mainly acts as an autoantigen, capable 
of activating the CD1d-restricted T cells involved in atherosclerosis. It indicates the 
autoimmune responses in atherosclerosis. On the other hand, in a high lipid 
environment the CD1d-restricted T cells produces inflammation in the spleen and can 
further affect heart function by activation of the NF-kB pathway. Hence, 
CD1d-restricted T cell responses to autolipid antigen and mediated inflammatory 
signal may represent a new molecular pathway that triggers cardiovascular tissue 
injury in atherosclerosis and hyperlipidemia.    
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